Subclinical hepatic encephalopathy: diagnosis, clinical implications, and intervention by Guero Guillen, J.C.
SUBCLINICAL HEPATIC ENCEPHALOPATHY: 
DIAGNOSIS, CLINICAL IMPLICATIONS, 
AND INTERVENTION 
J.C. QUERO GUILLEN 
Cover designed by Rafael Algar Castillo 
SUBCLINICAL HEPATIC ENCEPHALOPATHY: 
DIAGNOSIS, CLINICAL IMPLICATIONS, AND 
INTERVENTION 
SUBKLINISCHE HEPATISCHE ENCEFALOPATHIE: 
DIAGNOSTIEK, KLINISCHE BETEKENIS EN INTERVENTIE 
P"oefschrift 
ter verkrijging van de graad van doctor aan de 
Erasmus U niversiteit Rotterdam op gezag van de 
rector magnificus 
Prof. Dr P.W.C Akkermans M.A. 
en volgens besluit van het College voor Promoties 
De openbare verdediging zal plaatsvinden op 
woensdag 7 mei 1997 om 15.45 lIur 
door 
Juan Carlos Quero Guillen 
geboren te Melilla 
PROMOTIECOMMISSIE 
Promotor: Prof. Dr S.W. Schalm 
Overige leden: Prof. J.H.P. Wilson 
Prof. Dr C.H. Gips 
Prof. Dr J. Pas schier 
Para mis padres, 
Rubichi, 
y Rosa Maria 
BAC II 
BAEP 
BCAA 
BI Des 
CI 
CRTS 
DST 
EEG 
GABA 
HE 
MDF 
NCT-A 
NCT-B 
P300 
PBC 
PSE-index 
SDT 
SHE 
SIP 
SRTL 
SSEP 
SWN 
SWW 
TMT-A 
TMT-B 
VEP 
WAIS 
LIST OF ABBREVATIONS 
Blood Ammonia Checker II 
brain stem auditory evoked potentials 
branched-chain amino acids 
Block Design Test 
confidence interval 
Choice Reaction Time to Sound 
Digit Symbol Test 
electroencephalogram 
gamma amino butyric acid 
hepatic encephalopathy 
mean dominant frequency 
Number Connection Test part A 
Number Connection Test part B 
P300 event-related potentials 
primary biliary cirrhosis 
portal systemic encephalopathy index 
Symbol Digit Test 
subclinical hepatic encephalopathy 
Sickness Impact Profile 
Simple Reaction Time to Light 
somatosensory evoked potentials 
speed of writing numbers test 
speed of writing words test 
Trail Making Test part A 
Trail Making Test part B 
visual evoked potentials 
Wechsler Adult Intelligence Scale 
CONTENTS 
Page 
1. Subclinical Hepatic Encephalopathy. An introduction. 9 
2. Determination of ammonia in capillary and arterial blood 
simultaneously using the Blood Ammonia Checker II. 37 
3. The diagnosis of subclinical hepatic encephalopathy in patients 
with cirrhosis using neurospychological tests and automated 
EEG analysis. 49 
4. Does subclinical hepatic encephalopathy affect daily functioning? 75 
5. Does a low-dose of lactulose improve quality of life in patients 
with liver cirrhosis? 99 
6. The effect of Helicobacter pylori eradication on the arterial 
ammonia levels in patients with liver cirrhosis. 115 
7. Subclinical Hepatic Encephalopathy: diagnosis, clinical 
implications, and update on intervention. A discussion. 129 
8. Summary 137 
Samenvatting 143 
Dankwoord 147 
Curriculum vitae 149 

Chapter I 
SUBCLINICAL HEPATIC ENCEPHALOPATHY. 
AN INTRODUCTION 
The contents of this chapter have been published in: 
Seminars in Liver Disease (1996, 16: 241-248) under the title Subclinical 
Hepatic Encephalopathy with the following authors: J.C. Quero and 
S.W. Schalm. 
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INTRODUCTION 
Hepatic encephalopathy (HE) is traditionally graded into four clinical 
stages of severity, ranging from lethargy, sleep and memory disturbances (grade 
1) to coma (grade 4).1 In addition to the clinical grading of HE, a subclinical 
stage has been described. In subclinical hepatic encephalopathy (SHE)* patients 
with cirrhosis, regardless of its etiology, exhibit various quantifiable 
neuropsychological defects, but have a normal mental and neurological status 
on standard clinical examination.2 
The prevalence of SHE has been reported to vary between 30% to 84% 
in patients with liver cirrhosis.'·13 This large variation in prevalence is due to 
differences in diagnostic methods, patients studied, and definitions of SHE used 
in the various studies. The diagnosis of SHE may have clinical importance as 
its presence may have a negative effect on the. capacity to perform manual 
labor,14 fitness to drive,15 or quality of life. I. In view of the reported high 
prevalence of SHE in patients with cirrhosis and its possible impact on daily 
life, routine assessment of early stages of HE is recommended, 8 because this 
syndrome may be reversible with treatment.4• 17·22 
Because our crude clinical experience, based mainly on outpatient 
observations, does not confirm the magnitude and severity of SHE as reported 
in the literature,2 the aim of this review is to examine critically the clinical 
significance of this entity, i.e., its prevalence and its impact on the quality of 
life . 
• (other names: subclinical portosystemic encephalopathy (SPSE), latent portosystemic 
encephalopathy, early hepatic encephalopathy, low-grade portosystemic 
encephalopathy) 
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DIAGNOSIS 
Up to 64 different diagnostic tests and 8 test batteries for the detection of 
SHE have been reported in the literature.23 The diagnostic tests can be roughly 
divided into two groups: psychometric tests and electrophysiological tests. 
Psychometric tests 
The hypothesis that mental changes can precede overt neurological 
symptoms of HE was first proposed by Zeegen et al. 3 They showed that 13 out 
of 34 patients (38 %) without clinical signs of hepatic encephalopathy after 
portal decompression surgery had an abnormal score in the Reitan trail making 
tests. Thereafter several psychometric tests have been applied to detect this 
subclinical stage of HE.'on The number of psychometric tests used in these 
studies ranged from 16 to 248 with a mean of 10 tests per study. Tarter et al 16 
used a test battery consisting of 26 tests, which took the patient approximately 
2.5 hours to complete. To avoid the possible effects of fatigue on the 
psychometric results, this test battery had to be performed in the course of 2 
days. 
A common finding of these studies is that psychomotor performance is 
impaired, while verbal ability is preserved in patients with SHE. '. 5, 8, 9, 11, IS The 
preservation of verbal ability explains the insensitivity of bedside mental status 
examination in detecting SHE5; this finding suggests that white collar workers 
are less affected by SHE in daily life than blue collar workers, IS which is in 
agreement with observations in patients with portal-systemic shunts, 14 
Among the many psychometric tests used for the detection of SHE, four 
are repeatedly selected because they appear to be of diagnostic value; the Digit 
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Symbol Test (DST) (Fig. I), the Block Design Test (BI Des), the Number 
Connection Test (NCT), and Reaction Times to Light or Sound (RT)." 5. 8.10·12. 
IS, 16 
/2111311121113111412141215111413151316121 
11161512141713151117161318151316141211181 
/9121716131518131615141917111815131618121 
17111913181215171411161714151812191614131 
Figure 1: Digit Symbol Test: a subtest of the Wechsler Adult Intelligence Scale \'IV AIS) 
which measures motor speed and accuracy. The patient is given a list of symbols associated 
with digits from 1 to 9 and is asked to fill in the blanks with the symbols that correspond to 
each number. The test score is the total number of correct sequential matchings of digits to 
symbols in a 90 seconds interval. A high score indicates a good performance. 
The NCT-A (Fig. 2) is the most widely used test for the detection of 
SHE. It is a derivative of the Reitan Trail Test,24 also known as the Trail 
13 
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Making Test (TMT). The test is simple to perform, but interpretation of the 
NCT score is difficult (vide infra).4-7. 10-12.25.2. In studies with well defined 
normal values'"10.12.2'.29 abnormal NCT-A scores were observed in 7% to 33% 
of patients with cirrhosis; abnormal test results were found more frequently in 
Child-Pugh grade B/C (10%) than in grade A (5%).29 The results of these 
studies more closely resemble our clinical impression of a patient population 
mainly comprised of well-compensated cirrhotics than the very high percentage 
of abnormal values reported in other studies. 
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Figure 2: Number Connection Test part A (NCT-A): measures cognitive motor abilities. 
Subjects have to connect the numbers printed on paper consecutively from I to 25, as quickly 
as possible. Errors are not counted, but patients are instructed to return to the preceding 
correct number and then carryon. The test score is the time the patient needs to perform the 
test, including the time needed to correct all errors. A low score represents a good 
performance. 
14 
1l1lrotiUCfioll 
Pitfalls 
It has been demonstrated that psychomotor test scores are influenced by 
age.'·' 30. 31 Therefore, the use of adequate age normalized values is essential for 
proper interpretation of psychometric test results (Fig. 3). Most studies do not 
apply adequate normal values, which could result in a high number of false 
positives (Le., patients incorrectly diagnosed as having SHE) in their 
population. Cut-off criteria, such as that used in the PSE-index32 which does not 
take age into account, can give rise to highly misleading results if applied to all 
age groups. 
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Figure 3: NCT-A scores/or 83 lIorll/ollllvlduols. The upper limit of normal is depicted 
by the solid line (95th percentile; established according to Ihe method of Hogg RV. Estimates 
of percentile regression lines using salary date. J Amer Statist Assoc 1975; 70: 56-9). The 
dotted line illustrates the observation that normal values should be less than approximately 
ten times the subject's age in decades. 
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Even for studies which take the effect of age into consideration, 
interpretation of the NCT-A score remains difficult, as published age-corrected 
normal values vary markedly (Table I). This can be explained by the difference 
in normal cut-off points (mean ± 2 SD, 95th percentile), the educational level 
of the population," 31 and the different versions of the NCT -A used. Although 
the principle of the NCT-A is always the same (Le., connecting consecutive 
numbers from I to 25 as quickly as possible), apparently standardized versions 
of the NCT-A are not equal in difficulty. This was illustrated in 42 consecutive 
cirrhotic patients without overt HE who performed two different commercially 
available versions of the NCT (NCT-A supplied by Duphar Laboratories 
Limited [Southampton, United Kingdom) and NCT -A supplied by Duphar 
Pharma GmbH & Co [Hannover, Germany3')). The mean difference between 
these tests was 9 seconds (Table 2). 
The NCT-B test, in which patients have to connect numbers and letters 
in consecutive order, has been reported to be one of the most sensitive tests for 
the detection of SHE." 2. Nevertheless, the specificity of the NCT-B is low, 
because a considerable proportion of the normal 'heterogeneous' population 
scores abnormal in this test. Furthermore, the need for normal values corrected 
for educational status30 appears even greater for the NCT-B than for the NCT-
A. To illustrate this, we asked 83 outpatients with cirrhosis to perform the 
NCT-B. Seven out of 19 foreign patients were not able to complete the test 
because of insufficient knowledge of the Roman alphabet. Of the remaining 76 
patients 18% scored abnormal in the NCT-Bj Dutch speaking foreigners had a 
test score three times (33 %) worse than native Dutch patients (11%) 
(unpublished data). 
16 
Table 1 Nonna! values (seconds) for various age groups and/or educational levels determined for several versions of the NeT-A. 
Trail Making Test 
Age groups (years) 20 -39 40 - 49 50 - 59 60 - 69 70 -79 years 
Davies30 21 -50 22 - 59 2S -<>7 29 - 104 38 - 168 
(values expressed as 10th to 90th percentile) 
Age groups (yean) 35 - 50 51- 60 61-70 2:.. 71 years 
Marchesini6 high education 28 ± 3 32 ± 3 34 ± 2 
(values expressed as mean ± standard error) 
[qw education 40 ± 6 46 ± 6 71 ± 9 86 ± 9 
Number Connection Test 
Age groups (years) < 35 35 - 50 51- 60 61-70 1:. 71 years 
Zeneroli30 high education 45.3 ± 13.3 56.2 ± 18.3 67.8 ± 19.5 
(values expressed as mean ± standard deviation) 
low education 51.5 ± 18.3 70.5 ± 28.2 85.9 ± 26.5 143.7 ± 67.2 265.2 ± 58.6 
Age groups (years) 20 - 39 40 - 49 SO - 59 60 - 69 years 
(values expressed as mean ± standard deviation) 
Yen'rJ 28.3 ± 14.6 32.4 ± 16.1 37.7 ± 15.7 42.1 ± 17.4 
Table 2: 
Chapter I 
Results (in seconds) of two different versions of the NCT-A performed 
simultaneously by 42 patients with liver cirrhosis without hepatic 
encephalopathy. 
mean ± SD range p vallie 
NCT-A (Duphar United Kingdom) 42.0 ± 15 
33.3 ± 13 
20 - 81 
< .00001 
NCT-A (Duphar Germany) 15 - 66 
Recently, the Figure Connection Test parts A and B (FCT) , which can 
be used to test illiterate individuals, was developed." Results of the FCT were 
similar to those of the NCT; however, an effect of education could still be 
demonstrated. 
Repetitive testing has also been shown to have an effect on psychometric 
test scores.20, 21,35 To abolish this learning effect during the follow-up of patients 
with cirrhosis, the use of different test variants of equal difficulty has been 
suggested.3I 
We conclude, therefore, that psychometric tests are not as simple and 
easy to interpret as has been suggested. Age, education, and a learning effect 
must be taken into account when interpreting the results. Furthermore, the term 
"bedside" tests is misleading because these tests should be performed in a sitting 
position in a quiet room with sufficient light. 
18 
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Electrophysiological tests 
Due to the above mentioned disadvantages of psychometric tests, several 
authors have proposed the use of electrophysiological methods as more 
objective tools for the detection of SHE.26. 28. 36. 37 Studies have been performed 
with visual-evoked potentials (yEP),12, 26.28.36-40 brain stem auditory-evoked 
potentials (BAEP),37, 38 somatosensory-evoked potentials (SSEP),27, 37,38 and 
P300 event-related potentials (P300) (Fig, 4).28,41,42 
o 300 600 
Latency (ms) 
Figure 4: PFP300 potellfials of the B stlllluli for olle persall frolll each of the study 
groups, The N250 and PFP300 latencies are markedly prolonged in the patients with 
compensated liver cirrhosis (C1.l), decompensated liver cirrhosis (C1.2), and hepatic 
encephalopathy (C2) compared with the potentials of a patient from the control group (NC); 
the amplitudes do not change significantly. (Kugler CF, Lollerer E, Peller J, Wensing G, 
Taghavy A, Hahn EG, Fleig EW. Visual event-related P300 potentials in early portosystemic 
encephalopathy. Gastroenterology 1992; 103: 302-10). P300 is defined as the first positive 
going peak after the Nl-P2-N2 complex between 250 and 500 msec after presentation of the 
stimulus. 
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The percentage abnormal results among cirrhotics without overt hepatic 
encephalopathy found in the various studies ranged from 0% to 63% for YEP, 
0% to 41 % for BAEP, 5% to 34 % for SSEP, and 14% to 78% for P300. 
Although evoked potentials seem less sensitive than psychometric tests, a higher 
specificity and positive predictive value has been suggested by Yen et al,27 who 
found that a larger percentage of patients with abnormal SSEP developed 
clinical overt HE compared with patients with an abnormal NeT-A. The results 
of these studies are apparently influenced by the different methodologies and 
patient populations studied. A detailed review of these evoked potentials studies 
has been published recently." In the last few years, the diagnostic value of the 
P300 latency has emerged, whereas confirmation of the diagnostic value of 
other types of evoked potentials has been very limited. The broad overlap of the 
evoked potentials results found in cirrhotic patients and healthy controls makes 
interpretation particularly difficult. J9 In contrast to the conventional evoked 
potentials, the response on event-related endogeneous evoked potentials, such 
as the P300, does not depend on the physical properties of the stimulus, but 
rather on the meaning of the stimulus to the patient. In P300 potentials, for 
example, the patients response to two different stimuli is measured. P300 
potentials are therefore considered sensitive in reflecting subtle cognitive 
dysfunction because they are electrophysiological markers of cognitive processes 
such as stimulus discrimination and evaluation. 
The electroencephalograph (EEG) has not played a major role in the 
diagnosis of SHE. However, the percentage abnormal EEGs among cirrhotics 
without HE varies from 8 % to 35 %,4.8,14,26,28,39,44 which is still a considerable 
proportion of the cirrhotic population, Furthermore, when adequate age-
20 
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corrected normal values are used for psychometric tests, the EEG yields two to 
three times more abnormal results than the NeT-AI'" 29 We prefer spectral 
analysis of the EEG (Fig, 5) above conventional EEG, because the former is 
less susceptible to interobserver or intraobserver variability and provides easily 
interpretable quantitative data, For the diagnosis of SHE, an elevated percentage 
theta activity is used,44 
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Figure 5: Examples of EEG power 'pectra for differellf grades of hepatic 
encephalopathy. Power spectra of cirrhotic patients without encephalopathy resemble those 
of healthy controls. The mean dominant frequency (MDF) decreases with increasing clinical 
grade of encephalopathy (peak frequency shifts to the lef!); MDF alone, however, cannot be 
used as a single parameter to grade hepatic encephalopathy. Grade 0 and grade I (both MDF 
;;, 6.4 c/sec) can be differentiated by means of the increased percentage of theta activity (;;' 
35 %) in grade 1. Patients with grade I and some with grade 2 abnormalities may lack 
clinical signs of hepatic encephalopathy, and are diagnosed as having subclinical hepatic 
encephalopathy (35% in this study). Patients with grade 3 to 4 can be differentiated from 
grade 2 by means of the increased percentage of delta activity (;;' 70%). (Van der Rijt CCD, 
Schalm SW, de Groot GH, de Vlieger M. Objective measurement of hepatic encephalopathy 
by means of automated EEG analysis. Electroenceph Clin Neurophysiol 1984; 57: 423-6) 
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Pitfalls 
An obvious disadvantage of electrophysiological tests compared with 
psychometric tests is the need for expensive, sophisticated equipment and well-
trained personnel. Furthermore, the results should be interpreted by experienced 
neurophysiologists. Although spectral analysis of the EEG, according to Van 
der Rijt et al,44 can be interpreted by a non-neurologist, quality control by 
neurophysiologists is still needed. In addition, the results of spectral EEG 
analysis reported in the literature cannot be compared because of differences in 
methodology, such as bandwidth and filters. 2o• 28. 44 Methodological variations 
are even larger for evoked potentials. 
Several investigators have used a combination of psychometric and 
electrophysiological tests for the diagnosis of SHE." 14.27.28.39.44 Their results 
show that there is not a complete overlap of abnormal psychometric and 
electrophysiological test results. Therefore, a combination of psychometric and 
electrophysiological tests should be used for the detection of SHE because each 
method probably assesses a different brain function. 
CLINICAL SIGNIFICANCE 
Implications for daily life 
Since consciousness is not disturbed, the clinical significance of SHE is 
less obvious than that of overt HE. The characteristics of SHE are impaired 
psychomotor performance with preserved verbal ability. Kardel et al 14 have 
shown that impaired psychomotor performance has more implications for 
22 
illlroliuClioll 
patients performing manual work than those involved in intellectually 
demanding work. In addition, Schomerus et al" postulated that the psychomotor 
defects found in patients with SHE could have a negative effect on fitness to 
drive. They performed a study in which 40 patients with cirrhosis, divided into 
three groups (alcoholic cirrhosis, nonalcoholic cirrhosis, cirrhotics with minor 
EEG changes), and a control group of patients with alcoholic pancreatitis 
underwent an extensive neuropsychological test battery (24 tests, 102 variables 
studied!). On the basis of the results of this neuropsychological examination, the 
investigators concluded that 60% of the cirrhotics were unfit to drive a car and 
that the driving capacity of 25 % was questionable. Of the cirrhotic patients with 
minor EEG changes, 90% were considered unfit to drive. Unfortunately, the 
authors do not describe the method used to assess driving fitness in their article, 
which makes their conclusions less convincing. 
Doubts about whether an impaired fitness to drive exists in SHE has been 
markedly boosted by two recent publications.'" 46 O'Neill" reported little 
correlation between psychometric tests and driving ability, and suggested using 
'activity of daily living scales' for this purpose. Srivastava et al46 performed a 
study in which the driving fitness of 15 patients with liver cirrhosis was 
assessed "on the road". The investigators used the five tests most highly 
recommended in the literature (BI Des, DST, NCT-A, NCT-B, Visual Reaction 
Time) to diagnose SHE. Driving fitness was assessed not only by a simulator, 
but also by a real driver's examination in an automobile. Patients with liver 
cirrhosis and SHE (n=9) did not drive less well when compared with 15 
healthy controls. A remarkable finding of this study was one patient (a taxi 
driver!) who had extremely bad psychometric test results but gave a good 
driving performance. 
23 
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Another way of evaluating the clinical implications of SHE is 
questionnaires that measure the effect of illness on daily life. 16. 17 Tarter et al '6 
measured quality of life among 30 patients with liver cirrhosis using the 
Sickness Impact Profile (SIP) questionnaire. Cirrhotic patients reported more 
impairment in several SIP categories (sleep and rest, recreation and pastimes, 
body care and movement) compared with 10 patients with Crohn's disease. 
Recently, we have confirmed their findings, comparing 26 cirrhotic patients 
with SHE with 57 cirrhotic patients without SHE.47 A study is in progress to 
determine whether the diminished quality of life is due to SHE or to the 
diminished liver function in these patients. 
Natural History 
Although it is theoretically assumed that SHE will develop into clinically 
overt HE, few long-term follow-up studies have been performed to document 
this sequence. 
In a noncontrolled study, three out of nine cirrhotic patients with SHE 
developed HE during a one-year follow-up period.' All patients had a surgical 
portal-systemic shunt, which is in itself a major risk factor for HE. Yen et al27 
performed a 6-month follow-up study of 44 patients with decompensated liver 
cirrhosis. Fifty percent of these patients developed HE within 6 months, 
illustrating the severity of the liver disease. Significantly, more patients with 
abnormal NCT -A or SSEP on initial examination developed overt HE (72 %) 
than patients without abnormalities (21 %). The specificity of the SSEP was 
considered higher than that of the NCT -A, as only 5 % of the patients without 
HE had an abnormal SSEP, whereas 32% had an abnormal NCT-A. 
24 
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TREATMENT 
Several intervention studies using nonabsorbable saccharides,17-19 dietary 
manipulation,4. 20 and branched-chain amino acids (BCAA)21. 22 have been 
reported, all of which document some improvement in SHE after treatment. 
Nonabsorbable saccharides 
For the treatment of SHE, McClain et al 17 compared lactulose with a 
placebo in 32 patients with liver cirrhosis. Patients were treated for 3 months. 
In both treatment groups the medication dose was titrated to achieve three soft 
stools daily. Efficacy of treatment was assessed with five psychometric tests 
(Trailmaking Tests A and B [TMT-A, TMT-B], Speed of Writing Words and 
Numbers [SWW, SWN], and the Digit Symbol Test [DST]). Patients were not 
preselected on the basis of abnormal psychometric tests. In addition, the Katz 
Social Inventory was used to assess how these patients functioned within their 
environment. Ten patients dropped out of the study, leaving a total of 10 
evaluable patients in the lactulose group and 12 patients in the placebo group. 
There was a significant II % to 20% improvement in three out of five 
psychometric tests (TMT-A, SWW, DST) in the treatment group compared with 
baseline values. No improvement in psychometric tests was seen in the placebo 
group. In addition, neither the lactulose nor the placebo group showed an 
improvement in daily functioning as measured by the Katz Social Inventory 
score. 
Morgan et ailS performed a randomized cross-over study with lactulose 
and lactitol in 20 stable patients with liver cirrhosis. Patients were randomized 
to receive either lactulose or lactitol for 2 months; after a wash-out period of 
25 
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4 weeks they crossed over to the other saccharide and were treated for an 
additional 2 months. The medication dose was adjusted to produce two semi-
soft stools daily. Efficacy of treatment was assessed using conventional EEG 
and five psychometric tests (NCT, DST, Digit Copying [DC], two-choice visual 
reaction time test, perceptual maze test). All patients had abnormal scores for 
at least two psychometric tests at baseline evaluation. Six patients dropped out 
of the study, leaving a total of 14 evaluable patients. Both lactulose and lactitol 
showed only significant improvement in the Digit Symbol test. 
Salerno et all. studied the long-term efficacy of two dosage schedules of 
lactitol in SHE. Twenty-eight patients were randomized to receive either 0.3 
g/kg or 0.5 g/kg bodyweight lactitol daily for 5 months. Treatment efficacy was 
assessed by venous ammonia levels, EEG, psychometric tests (NCT, DST, 
cancelling As), and the PSE-index. All patients had SHE, defined as at least 
two abnormal psychometric tests. Six patients dropped out of the study, leaving 
11 evaluable patients in each treatment group. Both the low-dose and high-dose 
lactitol groups showed significant improvement in the venous ammonia levels 
and cancelling As test. Improvement in the NCT and DST was found only for 
patients on high-dose lactitol. All efficacy parameters returned to baseline 
values 1 month after treatment. Subjective improvement in concentration was 
reported by only 2 out of II patients on high-dose lactitol. 
Dietary manipulation 
Rikkers et ai' were the first to document reversibility of 
neuropsychological abnormalities after treatment. In this open study, five 
postshunt cirrhotic patients were put on an isocaloric zero protein diet for 7 
days after a 2-week baseline period on a 40 g/day protein diet. Efficacy 
26 
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parameters were four psychometric tests (TMT-A and B, Simple Reaction Time 
to Light [SRTL], Choice Reaction Time to Sound [CRTSJ) and fasting plasma 
ammonia. A significant improvement after treatment was found for three 
psychometric tests (TMT-A and B, CRTS) and the ammonia concentration. 
De Bruijn et aI'° performed a cross-over study with eight patients with a 
surgical portal-systemic shunt, who received an animal, vegetable, or mixed 
protein diet for I week. Treatment efficacy was assessed with EEG 
(conventional and computerized) and the Trailmaking Tests A and B. Compared 
with the animal protein diet, the vegetable protein diet gave an improvement in 
the peak frequency of the computerized EEG. There was not a significant 
difference in either the TMT-A and B or the conventional EEG between the 
various diet groups. 
Branched-chain amino acids 
Egberts et al21 performed a cross-over study with oral BCAA using 22 
patients with liver cirrhosis without clinical signs of HE. In all cases, impaired 
driving capacity was suspected. Patients received either BCAA or placebo for 
I week and then crossed over to the other treatment group. Laboratory and 
clinical examinations were performed on the first and last days of each 
treatment period and 4 weeks after the last treatment day. Efficacy of treatment 
was assessed by venous ammonia levels, EEG, and a neuropsychological test 
battery consisting of 15 tests. In addition, driving capacity was assessed on the 
basis of the psychometric test results. No significant decrease in the ammonia 
level or improvement in the EEG was seen after treatment with BCAA. Seven 
out of 15 psychometric tests improved during BCAA treatment; 5 out of 15 
tests deteriorated 4 weeks after the BCAA treatment period. A remarkable 
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finding of this study was the fact that three psychometric tests (NCT, Number 
Revision Test, d2 test) showed statistically significant improvement due to a 
learning effect. Driving capacity did not change significantly with BCAA. 
The long-term effects of BCAA in SHE were studied by Plauth et al,2' 
Twenty-three patients with liver cirrhosis and suspected impaired driving 
capacity were treated for 8 weeks in a placebo-controlled cross-over study. 
Efficacy parameters were venous ammonia levels, a neuropsychological test 
battery, and assessment of driving capacity. Due to 6 dropouts, 17 patients were 
evaluable. Compared to the placebo, BCAA treatment resulted in a significant 
improvement in 3 (DST, Digit Table, long pins) out of 12 psychometric tests. 
The NCT was susceptible to a significant learning effect in both groups; 
however, there was no difference in improvement between BCAA and placebo. 
Long-term BCAA treatment did result in a significant improvement in driving 
capacity. 
Does treatment of SHE improve daily functioning and does it prevent the 
development of clinically overt HE? The abovementioned studies" 17-21 
demonstrated moderate improvement in fewer than half of the psychometric 
tests performed. In addition, only three studies 17• 20. 21 assessed whether 
treatment was effective against the assumed social and clinical complications of 
SHE. One of these studies concluded that long-term treatment of SHE improves 
driving capacity"; however, the methodology of assessing driving capacity is 
not described and, therefore, immediate acceptance of such a conclusion is not 
justified. 
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DISCUSSION 
Subclinical hepatic encephalopathy is an entity which was first described 
in the early 1970s in patients with a portal-systemic shunt.3• 4. 14 Evidence shows 
that psychomotor performance is disturbed in patients with SHE and that 
cognitive" or subcortical4' impairment is responsible. However, the application 
of various diagnostic methods has caused confusion regarding the incidence and 
significance of SHE. 
The reported prevalence of SHE depends on the kind and number of 
diagnostic tests, the population tested, and the definition of SHE used. The 
prevalence of abnormal psychometric tests is much lower when adequate age-
related percentile scores are used. If adequate normal values are used, then less 
than 10% of the patients will usually have an abnormal score for the NCT-A.'2. 
2'.29 A combination of various tests as a diagnostic screen for SHE has been 
suggested by several authors.2. 12.28 Among the proposed psychometric tests are 
the NCT-A, NCT-B, Digit Symbol Test, Block Design Test, and Reaction 
Times to Light or Sound. The first three tests are easily administered "pencil 
and paper" tests, which can be performed during an outpatient control visit. The 
problem with these tests lies in the interpretation of the test score; age-adjusted 
normal values for the test are a minimum requirement. Even then, the NCT-B 
is not generally applicable to the entire population because of its strong 
educational and cultural bias. 
Should we use psychometric tests, electrophysiological tests, or a 
combination of both to detect SHE? Psychometric tests seem more sensitive 
than electrophysiological tests, but their specificity is probably lower.'" 21 In 
addition, complete overlap between abnormal psychometric test results and 
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abnormal electrophysiological tests does not exist. This suggests that a 
combination of these two methods should be used for the detection of SHE. 
The psychometric and electrophysiological diagnostic tests which should 
be used depends on local circumstances and experience. Weissenborn et al" 
suggest the NCT-B and P300 evoked potentials for detecting SHE. We have 
chosen to use the NCT-A, SDT, and spectral-EEG as diagnostic tools. 
We define SHE as an abnormal electrophysiological test and/or 
psychometric test. This is an arbitrary definition, since there is no 'gold 
standard' for diagnosis. A good diagnostic test should tell us something about 
the severity of the disease, the subsequent clinical course or prognosis of the 
disease, and the response to therapy. 49 How do these criteria apply to the 
diagnostic tests used for the detection of SHE? 
SHE does seem to correlate with liver function4• 5. 12. 15. 50." and is found more 
often among patients with more severe liver disease. 12. 29 Therefore, 
development of SHE into clinically overt HE is likely. However, it must yet be 
determined whether SHE offers additional information on the clinical course and 
prognosis of the disease compared with the simple and fully investigated Child-
Pugh classification. 
Should we diagnose and treat SHE because the impaired performance 
skills could be dangerous for the patient and society? Treatment of SHE may 
be beneficial for cirrhotic patients with stable liver disease and impaired 
performance at work or in daily life. However, only a minority of these patients 
have SHE, and not all of them will experience an impaired quality of life. In 
patients with SHE and progressive liver disease, treatment should be directed 
towards improvement of liver function (e.g. antiviral therapy, transplantation), 
as this appears to determine the quality of life and prognosis rather than SHE 
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itself. 
Further studies, in which the clinical relevance of this subclinical entity 
is evaluated, are needed before more widespread treatment of SHE can be 
recommended. 
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DETERMINATION OF AMMONIA IN CAPILLARY AND ARTEIUAL 
BLOOD SIMULTANEOUSLY USING THE 
BLOOD AMMONIA CHECKER II 
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Advances in hepatic encephalopathy and metabolic nitrogen exchange, 
Capocaccia L, Merli M, Riggio 0 (Eds,), CRC Press, Boca Raton, USA (1995; 
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INTRODUCTION 
The ammonia determination in arterial blood correlates best with the 
severity of hepatic encephalopathy. I Arterial punctures for investigational 
purposes, however, can cause medical ethical problems in some european 
countries. 
Recently, the Blood Ammonia Checker (BAC) II has been introduced, 
which determines blood ammonia quantitatively in 20 "I of blood. 2" Because 
of the small amount of blood needed, this apparatus is suitable for measuring 
the ammonia content in capillary blood. However, it needs to be investigated 
whether capillary blood ammonia levels correspond closely to arterial ammonia 
levels and if they are reliable in monitoring patients with liver disease. 
We present the results of a pilot study comparing capillary with arterial 
ammonia levels in patients with liver disease and controls using the BAC II 
system. 
MATERIALS AND METHODS 
Microdiffusion method 
The Blood Ammonia Checker (BAC) II system (Kyoto Daiichi Co., Ltd., 
Kyoto, Japan) consists of a reflectance meter and special reagent strips for 
blood ammonia determinations. The method is based on alkaline liberation of 
gaseous ammonia, passage of gaseous ammonia through the pores of a so-called 
spacer and finally bromocresol colouring and colorimetry. 
The method uses 20 "I of whole blood and after exactly 200 seconds the 
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result can be read. This BAC II can be used as a bedside procedure. 
The arterial blood ammonia reference values using this method amounted to 7 -
28, median 21 Jtmol/I,2· 3 
Reference methods 
For reference two enzymatic methods based on the same enzymatic 
conversion of NADPH to NADP+ have been used, viz. the Du Pont aca method 
and the Boehringer Mannheim procedure. 5 Reference values for the arterial 
ammonia concentration using these methods are 10 - 30 Jtmol/l and 9 - 37 
Jtmol/l, respectively. In contrast to the BAC II method, both enzymatic methods 
measure ammonia in plasma. 
Subjects 
The comparison of the ammonia content in capillary and arterial blood 
was performed in 12 controls without liver disease (6 healthy volunteers and 6 
lung patients in which arterial puncture was done for routine blood gas 
analyses) and 16 patients with liver disease, portosystemic shunting and elevated 
NH3 or with acute liver failure. 
Serial measurements of ammonia in capillary blood for 3 days was 
performed in 14 fasting healthy controls. 
Procedure for drawing capIllary blood 
The fingertip was cleansed thoroughly because sweat has been reported 
to have a high ammonia content of about 3 mmol/l, which is 100-200 times 
higher than normally found in blood.6 After thoroughly washing the hands with 
water (in a few patients also with soap), the finger was cleaned with 
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chlorhexidin in 70 % alcohol and dried using a dry tissue (Medipress, Van 
Heek Medical, Losser, Holland). The fingertip was pricked with an automatic 
lancing device (Ames Autolet, Owen Mumford Ltd., Woodstock, England) and 
cleaned after the first drop of blood using a dry tissue. Twenty Itl of the second 
drop of blood was taken with an Eppendorf pipette with Eppendorf disposable 
tips for the NH, determination with the BAC II. 
Procedure for drawing arterial blood 
Arterial puncture was performed in the radial artery in the hyperextended 
wrist using a 2.0 ml syringe with a 0.6 mm x 16 mm needle (both Monoject, 
Sherwood Medical, Ballymoney, Northern Ireland). Prior to the puncture the 
syringe was flushed with I drop sodium-heparin (Thromboliquine, Organon 
Teknika, Oss, The Netherlands). After drawing blood the syringe was gently 
rotated and immediately placed on crushed ice. Approximately 0.1 ml blood 
was transferred from the syringe to a 1.5 ml Eppendorf micro test tube. Twenty 
Itl blood was taken with an Eppendorf pipette from this tube and used for the 
bedside NH, determination with the BAC II. The remaining blood in the syringe 
was used for the lab based NH, determination with the 'Du Pont Automatic 
Clinical Analyzer (aca)' procedure (only in Rotterdam). In 6 controls from the 
University Hospital Groningen the arterial NH, was measured with the 
'Boehringer Mannheim' procedure. 
Capillary and arterial blood was drawn in the morning in the fasting 
patient within a 10 - minute period. Bedside and lab based measurements were 
done within 15 minutes. 
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RESULTS 
Table 1 shows the results of the ammonia measurement in capillary and 
arterial blood. The mean difference between capillary and arterial ammonia 
measured with the BAC II was 33 JtmoIlI (SO 23.5, range 2 - 71 JtmoIlI) in 
controls and 23 JtmoIlI (SO 26.2, range -27 - 68 JtmoIlO in patients with liver 
disease. The mean difference between arterial ammonia measured with the BAC 
II and the enzymatic procedures in the control and patient group was 6 JtmoIlI 
(SO 11.0, range -8 - 33 JtmoIlI) and 10 JtmoIlI (SO 21.1, range -27 - 45 
JtmoIlI) respectively. 
Table 1: Capillary versus arterial ammonia (J<molll) measured with the BAC II and 
enzymatic methods ('aca' or 'Boehringer-Mannheim' procedure) in 12 controls 
and 12 patients with cirrhosis of the liver and portosystemic shunting. 
mean range SD mean range SD 
COlllro/S Patiellls 
Capillary NH, (BAC II) 64 24-102 25.1 161 88-286' 69.0 
Arterial NH, (BAC II) 31 15-57 10.5 141 3-286' 73.1 
Arterial NH, (enzymatic) 26 12-43 7.7 131 62-302 69.7 
, Upper detection limit of the BAC II apparatus. 
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Figure 1 illustrates the relation between capillary and arterial anunonia levels 
in both groups. Capillary and arterial ammonia BAC values of both groups are 
plotted in Figure 2. Although we found a reasonable correlation (r = 0.92) 
between capillary and arterial ammonia levels measured with the BAC II, the 
difference in the mean concentration in capillary and arterial blood was 
statistically significant (p = 0.0005 in the controls, p = 0.004 in the patients, 
paired t-test). The differences between the arterial anunonia levels measured 
with the BAC II and the enzymatic procedures were not statistically significant 
(p = 0.11 in the controls, p = 0.13 in the patients, paired t-test). 
ammonia 
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Figure 1: 
aca BAC II BAC II aca BAC II BAC II 
CONTROLS PATIENTS 
Values for arterial (determined with the BAC II and enzymatically) and 
capillary ammonia levels (only determined with the BAC II) in 12 controls and 
12 patients (arrows indicate the upper detection limit of the BAC II). 
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Figure 2: Capillary versus arterial ammonia measured with the BAC II in patients with 
cirrhosis of the liver and controls. 
The capillary blood ammonia levels in 14 healthy controls during 3 
consecutive days are shown in Table 2. The difference in ammonia level ranged 
from 0 to 84 "mol (median value 19 "mol) and the mean coefficient of 
variation was 29.6 %. 
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Controls 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
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Day-to-day variation of capillary ammonia (J<mol/l) measured with the BAC 
II in healthy controls. 
day 1 day 2 day 3 mean CV, %' 
99 83 72 85 16.0 
53 74 23 50 51.2 
76 133 88 99 30.4 
101 58 75 78 27.8 
41 56 35 44 24.6 
45 34 118 66 69.5 
36 57 35 43 29.1 
45 57 35 46 24.1 
53 53 76 61 21.9 
36 37 64 46 34.8 
69 39 32 47 42.1 
37 51 60 49 23.5 
56 62 61 60 5.4 
41 53 52 49 13.7 
• coefficient of variation 
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DISCUSSION 
The ammonia determination in arterial blood reflects the severity of 
hepatic encephalopathy better than that in venous blood.' However, in contrast 
to arterial blood gas studies, there is much resistance to perform arterial 
punctures to measure anunonia in patients with liver disease. Capillary levels 
have been suggested to correspond closely to arterial levels and could be an 
acceptable alternative.7 Peltola et ai' performed a study in which capillary and 
venous ammonia levels were compared using the BAC II. The ammonia 
concentration in capillary blood was considerably higher than that in venous 
blood and sweat was considered as the contaminating source. However, it is not 
clear from the text if measures were taken to prevent this contamination. 
Huizenga et al9 found that capillary ammonia levels were not statistically 
significant from arterial ammonia levels after thorough cleansing of the fingertip 
with chorhexidin before puncture. 
We performed a study to determine whether capillary ammonia levels 
measured with the BAC II, after thoroughly washing the hands and cleansing 
the fingertip with chlorhexidin in 70 % alcohol, agree with arterial ammonia 
levels and are reliable in monitoring patients with liver disease. Three Dutch 
centers participated in this pilot study and found similar results. The data 
showed a correlation (r = 0.92) between capillary and arterial ammonia in a 
patient and a control group, however, agreement was poor as the capillary 
ammonia levels were considerably higher than the arterial ammonia levels. Both 
in the control and patient group the differences between capillary and arterial 
ammonia levels were statistically significant. Furthermore, capillary ammonia 
measurements during 3 consecutive days in 14 healthy controls showed poor 
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reproducibility. Interpretation of these data would have been easier if serial 
arterial ammonia levels in the controls were available, but this was not possible 
due to medical ethical reasons. However, the results showed such a marked 
variation indicating that the reproducibility of capillary ammonia levels is 
probably low. 
The finding that the capillary ammonia concentration was lower than the 
arterial ammonia concentration in 4 patients (Fig. 2), lead us to the conclusion 
that this might have been venous capillary blood, as venous ammonia levels are 
lower than arterial ammonia levels in cirrhotics. I Capillary values could have 
corresponded better to arterial values if capillary blood had been arterialized by 
holding the hands in a bath of warm water during 10 minutes. However, this 
needs further investigation. 
We conclude that, using the described cleansing and puncture procedure, 
capillary ammonia measurements with the BAC II are unreliable for monitoring 
patients with hyperammonemic diseases. Our experience suggests that ammonia 
should be measured from arterial blood. 
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THE DIAGNOSIS OF SUBCLINICAL HEPATIC ENCEPHALOPATHY 
IN PATIENTS WITH CIRRHOSIS USING NEUROPSYCHOLOGICAL 
TESTS AND AUTOMATED ELECTROENCEPHALOGRAM ANALYIS 
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ABSTRACT 
Neuropsychological tests used for the assessment of subclinical hepatic 
encephalopathy (SHE) may overdiagnose SHE because scores are usually not 
corrected for age. The aim of this study was to estimate the prevalence of SHE 
using 2 easy administrable psychometric tests (Number Connection Test part A 
[NCT -A], Symbol Digit Test [SOT]) with age related normal values. In 
addition, spectral electroencephalogram (EEG) was used, which is the in-house 
electrophysiological method for quantifying encephalopathy. 
One hundred and thirty-seven consecutive patients (mean age 49 years, range 
17-77) with cirrhosis without any clinical signs of encephalopathy, were 
screened for SHE. In addition, the Child-Pugh score and the arterial blood 
ammonia were determined. Patients with concurrent use of alcohol, 
benzodiazepines or anti-epileptics were excluded. 
Fifty percent of the patients had an abnormal NCT according to the standard 
recommended procedure, in contrast only 7 % of the patients had an abnormal 
NCT when scores corrected for age were used. Combining the results of the 
spectral EEG and the psychometric tests corrected for age yielded a higher 
prevalence of SHE (23%) than when each test method was used alone (17% vs. 
10% abnormal, respectively). Severity of liver disease correlated with the 
presence of SHE, because the prevalence of abnormal tests increased from 14 % 
in Child-Pugh grade A to 45% in Child-Pugh grade B or C. Age above 40 
years and an elevated blood ammonia level were significant determinants related 
to an abnormal EEG. We conclude that the NeT uncorrected for age markedly 
overdiagnoses SHE and, therefore, should not be used as a test for the 
screening of SHE. Using a combination of spectral EEG and two psychometric 
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tests with age-corrected normal values a low prevalence of SHE in patients with 
Child A liver cirrhosis is found. Older patients with an elevated arterial 
ammonia are more prone to develop SHE than younger patients with an equal 
arterial ammonia concentration. 
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INTRODUCTION 
Hepatic encephalopathy (HE) is a serious complication of advanced liver 
disease and refers to neuropsychiatric abnormalities (such as disorders of 
personality, altered levels of consciousness, impairment of intellectual function), 
and neuromuscular dysfunction (asterixis) because of liver insufficiency. I 
Traditionally HE is graded into four clinical stages of severity, ranging from 
abnormal behavior to coma.2 In addition to the clinical grading of HE, a 
subclinical stage has been descibed, in which patients with cirrhosis, regardless 
of its cause, show a number of quantifiable neuropsychological defects, yet have 
a normal mental and neurological status on global clinical examination.'-13 The 
prevalence of this subclinical hepatic encephalopathy (SHE) has been reported 
to vary from 30%13 to 84%," depending on the tests and population used. 
The neuropsychological defects found in SHE may have a negative effect 
on patients' daily life. 6. 14 In addition, these defects are considered to be a 
preclinical stage of clinical manifest HE." 9. J5 In view of the reported high 
incidence of SHE in patients with cirrhosis and its possible impact on daily life, 
routine assessment of early stages of HE is recommended." 6, 9, 16 as this 
syndrome may be fully reversible with treatment." 17-20 However, the extensive 
neuropsychological test batteries used in most studies (up to 21 different 
psychometric tests!9), are not suitable for a fast routine screening in an 
outpatient clinic. Conn21 suggested to use the Number Connection Test (NCT) 
as a sole psychometric test for quantifying HE. Other investigators,,9, 12, 13,22 
have proposed to use a combination of two to three psychometric tests as a 
diagnostic screen for SHE. As neuropsychological performance is known to be 
influenced by age, 2'.2' education,>' and repetitive testing,21 several investigators 
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have used neurophysiologial tools such as evoked potentials'" 25, 26 or 
quantitative electroencephalogram (EEG) analysis2' for the diagnosis of SHE, 
However, controversy exists in literature whether these neurophysiological 
methods are as sensitive as psychometric tests,28, 2. 
The aim of the present study was to determine the prevalence of 
neuropsychological and neurophysiological defects in stable cirrhotic patients 
attending a university hospital outpatient clinic, Two psychometric tests with 
age-corrected normal values (NCT part A3o, Symbol Digit Test3l ) were selected 
to be used as a neuropsychological screen, These two tests are easy to 
administer, have a reported high sensitivity in detecting SHE,3.5, 8,9, 12, 13 and can 
be performed within 5 minutes at the outpatient clinic, Spectral analysis of the 
EEG, which is the standard in-house electrophysiological method for grading 
HE,>' was used as a screen for neurophysiological defects, In addition, the 
arterial ammonia concentration was determined in each patient to assess whether 
the defects found at screening could be considered because of liver insufficiency 
and/or portosystemic shunting; the Child-Pugh score was determined to assess 
the severity of the chronic liver disease, 
PATIENTS AND METHODS 
Subjects 
From January 1, 1992 to December 31, 1993, 137 consecutive biopsy-
proven cirrhotic patients (99 male, 38 female, mean age 49 years, SD 14, range 
17-77) without any clinical signs of HE attending the outpatient clinic of 
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Internal Medicine II and Hepatogastroenterology of the University Hospital 
Rotterdam-Dijkzigt were screened for SHE. The cause of the cirrhosis was 
chronic viral hepatitis in 62 patients, alcohol abuse in 31 patients, and other 
causes (e.g. auto-immune, primary biliary cirrhosis, cryptogenic) in 44 patients. 
Patients diagnosed by the investigators or their treating physician as active 
alcohol abusers (excessive alcohol intake in the preceding 6 weeks, or 
deterioration of the blood transaminase levels in the preceding outpatient control 
visits) and patients using benzodiazepines or anti-epileptics were excluded. 
None of the patients had evidence of neurological andlor psychiatric 
abnormalities on global clinical examination performed in each patient by the 
same examiner (J.C.Q.). Mental state assessment included state of awareness; 
"Is the patient perfectly alert and well orientated in time, place, and person?". 
The level of attention (primary memory) and concentration was assessed by 
asking the patient to subtract serial sevens from 100 and to repeat a series of 
six nonconsecutive numbers in the same order (a normal individual can easily 
remember seven numbers forwards). Secondary memory (recent memory, new 
learning, encoding) was tested by asking the patient to remember three objects 
and to repeat these several minutes later. Remote memory (ability to recall 
events of weeks or years ago) was assessed by asking the patient about past 
presidents, dates of wars, and events that affect everyone. 
Neuropsychological assesment 
Number Connection Test 
This test is a derivative from the Trail Making Test32 and measures 
cognitive motor abilities. In the NCT, subjects have to connect numbers printed 
on paper consecutively from I to 25, as quickly as possible. Errors are not 
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enumerated, but patients are instructed to return to the preceding correct 
number and then carryon, The test score is the time the patient needs to 
perform the test, including the time needed to correct the errors, A low score 
indicates a good performance, Age dependent normal values of this NeT'o have 
been developed in 681 persons without liver disease," Normal values are 
expressed as the mean ± 2 standard deviations, 
Symbol Digit Test 
This is a subtest of the Wechsler Adult Intelligence Scale (W AIS) and 
measures motor speed and accuracy," The patient is given a list of symbols 
associated with digits from I to 9 and is asked to fill in blanks with numbers 
that correspond to each symbol. The test score is the total number of correct 
sequential matchings of numbers to symbols in a 90-second interval. A high 
score indicates a good performance, Data of a 2,169 Dutch and Belgian persons 
serve as a reference group in the Netherlands," These normative data are 
expressed in percentiles, We considered a test result below the 2,5th percentile 
(Le" approximately the mean minus 2 standard deviations) as abnormal. 
After explanation of each psychometric test, an abbreviated demonstration 
test was administered to ensure that the patient understood the test correctly, In 
addition, the patient could adapt to the most convenient sitting position after the 
demonstration test, Attention was paid to the lighting of the room, and whether 
the patient was wearing his reading glasses, Patients likely to have difficulties 
performing the psychometric tests, such as those with neurological diseases or 
bad vision, were excluded from this study, 
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Neurophysiological assessment 
The EEG was recorded using standardized techniques (Nihon Kohden) 
while the patient, with the eyes closed, laid comfortably in a quiet room. When 
drowsiness occurred an auditory stimulus was applied by the EEG technician. 
Four electrodes were attached to the skin at the positions T3, T4, 01, and 02 
according to the international" 10-20 system". 35 Electrode impedance was kept 
lower than 5kfl. After applying the usual bandpass filters (0.53 - 35 Hz) 2 runs 
of 100 seconds each were recorded and compared for reproducibility. Artefact 
free recordings were selected and fed into a computer after analogue-digital 
conversion (sample frequency 102.4 Hz). Ten epochs of 10 seconds each were 
analyzed by applying Fast Fourier Transformation and the mean power 
spectrum calculated. Patients are graded in the different stages of HE on 
account of their mean dominant frequency (MDF), and the relative powers of 
I) and e activity. In a previous study27 we have validated this method in 51 
healthy controls (median age 41 years, range 21 - 78) and 66 patients with 
cirrhosis of the liver (median age 60 years, range 21 - 75). A e activity above 
the 97.5th percentile (i.e., approximately the mean plus 2 standard deviations) 
in controls (i.e., > 35 % 8 activity) was considered abnormal. 
Laboratory assessments 
The Child-Pugh score was used to assess the severity of liver disease.36 
Three biochemical variables (serum albumin, bilirubin, and prothrombin time) 
and two clinical characteristics (presence or absence of ascites and encep-
halopathy) determine the Child-Pugh score. Each variable is given 1 to 3 points, 
leading to scores ranging from 5 (excellent liver function) to 15 points (poor 
liver function). In addition, arterial ammonia levels were measured, using the 
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Dupont aca procedure" (Dimension SMS) (Dupont de Nemours; Wilmington, 
DE) or the Blood Ammonia Checker II (Kyoto Daiichi; Kyoto, Japan)." 
Statistical analysis 
Kappa was used as a measure of agreement of various tests. Wilcoxon's 
rank sum test or the Fisher Exact test were used to assess differences in clinical 
and laboratory characteristics of patient groups. Those variables reaching 
statistical significance in the univariate analysis, when clinical and laboratory 
data were compared between normal and at least one abnormal psychometric 
test, were selected for multivariate analysis using multiple logistic regression.39 
The same procedure was performed for EEG abnormality. The limit for 
statistical significance was set at p = 0.05. 
RESULTS 
None of the stable cirrhotic patients included in the study had clinical 
signs of hepatic encephalopathy. A good liver function, which was defined as 
Child-Pugh grade A, was present in 71 % of the patients. 
Fifty percent of the patients had an NCT score of more than 30 seconds, 
which is considered abnormal according to the Portal Systemic Encephalopathy 
index (PSE-index).'o However, the patients' age is not taken into account in this 
test, which is reflected by the fact that when age dependent normal values were 
used, only 7% of the patients scored abnormal. Table 1 summarizes the 
prevalence of abnormality in age-corrected psychometric tests and spectral EEG 
found in our population. 
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Table 1: Prevalence of abnormal psychometric tests and abnormal spectral EEG in 137 
cirrhotic patients without clinical hepatic encephalopathy. 
Diagnostic test n' tested n° abnormal % abnormal 
NCT-A (corrected for age) 137 9 7 
Symbol Digit Test 136 7 5 
L 1 abnormal psychometric test 137 14 10 
spectral EEG 137 23 17 
The agreement between the outcomes of the psychometric tests and 
spectral EEG was poor (K = 0.16). Only 16% (5/32) of the patients scored 
abnormal on both tests (Table 2). 
When patients were classified according to the severity of their liver 
disease, the percentage abnormality in psychometric tests increased from 6% 
in Child-Pugh grade A to 20% in Child-Pugh grade B or C. A 2 to 3 fold 
increase in abnormality in patients with a diminished liver function was also 
seen in the spectral EEG (Fig. I). Both findings were statistically significant 
(p = 0.03 and 0.01, respectively, Fisher Exact test). 
Clinical and laboratory characteristics of patients with abnormal 
psychometric tests and abnormal spectral EEG are summarized in Table 3. 
Males and females were equally distributed among the groups with normal and 
abnormal test results. 
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Table 2 Relation between psychometric tests and spectral EEG in 137 cirrhotic patients without clinical signs of hepatic encephalopathy. 
spectral EEG 
normal a!2nQrmaJ 
NCT nonnal 107 21 128 
abnormal 7 2 9 Observed agreement: (107+2)/137 = 0.80 
Kappa: 0.03 
114 23 137 
SDT normal III 19 130 
abnormal 3 4 14 Observed agreement: (111 +4)/137 = 0.84 
Kappa: 0.20 
114 23 137 
NeT and SDT normal 105 18 123 
NCTorSDT abnormal 9 5 14 Observed agreement: (105+5)/137 = 0.80 
Kappa: 0.16 
114 23 137 
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Figure 1: 
psychometric test spectral-EEG 
IOChiid A (n=97) OChiid BIC (n=40) I 
Percentage of abnormal test resuits in cirrhotic patients with a good liver 
function (Child-Pugh grade A, n=97) and cirrhotic patients with a diminished 
liver function (Child-Pugh grade B or C, n =40) 
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Table 3 Clinical and laboratory characteristics of the cirrhotic patients with normal 
and abnormal psychometric tests (3a) and spectral-EEG (3b). 
3a normal NCT and SDT abnormal NCT or SDT p value 
patient number 123 14 
dd: ~~ 88: 35 II : 3 0.8 
age (years) 48.1 ± 14 58.1 ± II < 0.05 
arterial NH, (pmol!l) 54.3 ± 33 70.2 ± 30 0.12 
Child-Pugh B or C 26% 47% < 0.05 
alcohol as etiology 21% 36% 0.31 
3b normal EEG abnormal EEG p value 
patient number 114 23 
dd: ~~ 81 : 33 18 : 5 0.6 
age (years) 47.2 ± 14 58.5 ± II < 0.01 
arterial NH, (pmol/I) 51.4 ± 32 75.1 ± 26 < 0.001 
Child-Pugh B or C 25% 52% < 0.05 
alcohol as etiology 19% 39% < 0.05 
In patients with alcoholic cirrhosis, a higher prevalence of abnormal tests 
was found compared to patients with nonalcoholic cirrhosis. Especially, the 
spectral EEG was more disturbed in the alcoholic group. A probable confounder 
in this finding was the severity of liverdisease, as a Child-Pugh grade of B or 
C was more frequently found in alcohol-induced cirrhosis than in nonalcohol-
induced (48% vs. 24%, respectively, p < 0.01). Therefore, multivariate 
analysis of the factors found to be significantly different between patients with 
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normal or abnormal test outcomes in the univariate analysis (age, ammonia, 
Child-Pugh class, alcoholic origin) was performed. Age remained the only 
significant factor related to abnormality in psychometric tests (Table 4). 
However, related to an abnormal EEG, the arterial ammonia concentration in 
addition to age was found to be a significant determinant (Table 4). Having 
patients grouped to age, Fig. 2 shows the probability of having an abnormal 
EEG according to both age and ammonia concentration arising from multiple 
logistic regression (Table 4). 
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Figure 2: 
10 20 40 80 
Arterial ammonia concentration (iJmolll) 
age> 60 yrs 
age.::: 60 yrs 
> 40 yrs 
age.::: 40 yrs 
160 
Probability of having an abnormal spectral EEG in different patient age groups 
according to the arterial ammonia concentration. 
(Note: logarithmically transformed horizontal axis) 
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Table 4 Multivariate analysis of the probability of abnormal test results. Odds-ratios are given for an abnormal EEG and for at least one 
abnormal psychometric tests (Odd-ratios of I indicate no association). 
abnormal spectral EEG 
QQds-ratiQ 
Age 1.8(~ 
Ammonia 3.1(b) 
Child-Pugh A' I 
BlC 1.1 
Alcoholic No' I 
Yes 1.7 
(a) as compared to 10 years younger 
(b) as compared to a 50% lower NH3 
(#) reference category 
o-value 
0.01 
0.01 
0.94 
0.36 
abnormal psychometric test 
Odds-ratio 
1.8(~ 
1.2(b) 
2.4 
1.6 
o-value 
0.04 
0.74 
0.26 
0.48 
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DISCUSSION 
According to literature, SHE is present in 30% to 84% of the patients 
with cirrhosis. 13. II Many physicians of our Hepatogastroenterology department 
doubt this reported high prevalence, because in their clinical experience most 
cirrhotic patients are normal at clinical examination and do not complain about 
diminished memory or concentration. Therefore, we performed a study to 
determine the prevalence of SHE in our patient population with cirrhosis. 
Our results confirm the presence of abnormal neuropsychological and/or 
neurophysiological abnormalities in patients with stable cirrhosis, however the 
prevalence found by us was lower than that reported in literature." 9, II. 12 We 
found that 10% of our cirrhotic patients scored abnormal in at least one out of 
two psychometric tests and that 17% had an abnormal spectral EEG. Using the 
established definition of SHE (i.e., neuropsychological and/or 
neurophysiological defects in patients with no signs of HE on clinical 
examination) 23 % of our cirrhotic patients had SHE. 
We believe our findings to be reliable, because the study including both 
neuropsychological and neurophysiological methods was performed in a large 
patient size. Furthermore, to avoid interobserver variability all patients were 
clinically and neuropsychologically assessed by the same examiner. In addition, 
spectral BEG analysis was used, which is the most objective method for EEG 
grading. Lastly, one of the most important conditions in selecting psychometric 
tests we fulfilled was the use o'f normal values corrected for age.23 • 24 Our results 
show the effect of age on neuropsychological performance; 50% of our patients 
had an abnormal standard NCT,'o but only 7% were abnormal when age-
corrected scores were used. Our results are in agreement with those of Koch et 
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al.,22 who used exactly the same NeT forms and age-corrected scores30 as in 
our study. 
With regard to spectral EEG as well as age-corrected NeT, our results 
confirm those of Weissenborn et al.,26 who performed a similar study in a much 
smaller study popUlation (n =29). 
Were the diagnostic methods used by us sensitive enough to detect SHE? 
We selected the NeT part A and SDT out of a large variety (approximately 
70!) of psychometric tests used in literature,'! because these two tests are 
reported to be sensitive, and can be administered easily during a routine control 
visit of a cirrhotic patient to a hepatology outpatient clinic. The NeT part B, 
in which patients have to connect numbers and letters in consecutive order, has 
been reported to be more sensitive than the NeT part A, because this test has 
an increased attentional load.'6 Therefore, exclusion of the NeT part B could 
have lowered our diagnostic sensitivity. However, this test could not be 
performed in all our patients, because part of our patient popUlation consists of 
foreign labourers, who are not familiar with the English alphabet. To document 
this, we administered the NeT part B in a subpopulation of 83 cirrhotic 
patients. Seven out of 19 foreign patients were not able to perform this test 
because of insufficient knowledge of the English alphabet. Of the remaining 76 
patients, 18% scored abnormal in the NeT part B. However, this result must 
be interpreted with caution because 33 % of the Dutch speaking foreigners 
scored abnormal in the NeT part B in contrast to 11 % of the native Dutch 
patients (data not shown). The percentage of abnormality in the NeT part B 
results probably would have been lower if we had also excluded patients with 
less than 8 years of education." We therefore selected only neuropsychological 
tests, the performance of which was hardly influenced by education and cultural 
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background. 
The number of diagnostic tests, the definition of SHE, and the patient 
population studied probably had their implications for the prevalence of SHE 
found. We found a SHE prevalence of 23%, defining SHE as at least one 
abnormal test out of two psychometric tests or an abnormal spectral EEG. 
Gitlin et al! found a prevalence of 70%, when SHE was defined as at least two 
abnormal tests out of 21. In addition, the definition of abnormal (values less 
than the 2.5th, 5th, or 10th percentile from a control group) could explain the 
wide range of SHE prevalence found in the various studies. 
The prevalence of SHE will also vary depending on the population tested. 
Our patient population consisted mainly of stable cirrhotic patients with a good 
liver function, which could explain the low prevalence of SHE found by us. 
Although controversy exists in literature, whether liver function correlates with 
SHE," 6. 22. 29. 42. 43 we found a significant increase in the prevalence of SHE 
from 14% (CI 7-21) in Child-Pugh grade A to 45% (CI 28-61) in Child-Pugh 
grade B or C. Another finding in our study was the poor overlap between 
abnormal psychometric tests and spectral EEG. It was not the intention of the 
study to determine whether psychometric tests are more sensitive than 
electrophysiological tests in diagnosing SHE. This question can not be answered 
from our results because we used prepublished normative data from different 
reference groups. However, we doubt whether a comparison between 
psychometric tests and electrophysiological tests is justified, because these tests 
probably assess different components of encephalopathy.44 If SHE is a 
preclinical stage of HE, theoretically the diagnostic tests should correlate with 
the severity of liver disease and the degree (level and/or duration) of exposure 
to causative factors. In our study, age and severity of liver disease were 
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significantly different in patients with or without abnormal psychometric tests. 
However, only age appeared to be significant after multivariate analysis. Age, 
arterial ammonia concentration, Child-Pugh grade, and alcohol as a cause of 
cirrhosis were significantly different for patients with or without an abnormal 
spectral EEG. After multivariate analysis only the patients' age and the arterial 
ammonia concentration were significant. This result, in association with the re-
emergence of ammonia as one of the major factors in the pathogenesis of HE, I 
strongly supports the use of spectral EEG in the detection of SHE. In a 
previous study,27 we did not find an age effect on the EEG in healthy controls, 
although common wisdom suggests that aging is associated with slowing of the 
EEG. Recent studies contradict this opinion and attribute the result of EEG 
slowing to age-related pathology (e.g. dementia, psychiatric illnesses, 
hypertension) rather than to aging itself." Quantified EEG studies in subjects 
carefully screened for cognitive disturbances fail to show substantial slowing of 
the EEG with age'·'''; only marked EEG changes in patients older than 80 years 
are described.'9 A possible explanation for the higher prevalence of SHE in the 
older patients could be that the aged brain is more prone to develop HE than 
the younger. In addition, the older brain may have been exposed for a longer 
time to the factors causing HE and subsequently have developed more severe 
cerebral impairment. JO Our study strengthens this hypothesis as we found a 
higher prevalence of abnormal EEGs in middle-aged patients compared with 
younger patients with an equal arterial ammonia concentration (Fig. 2). 
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Chapter 4 
DOES SUBCLINICAL HEPATIC ENCEPHALOPATHY AFFECT 
DAILY FUNCTIONING? 
The contents of this chapter have been submitted for publication under the same 
title with the following authors: J.C. Quero, I. De Bruijn, !.J.C. Hartmann, 
M.L. Essink-Bot, W.C.J. Hop, S.W. Schalm 

Does SHE (iffect daily fUnctioning? 
ABSTRACT 
Subclinical hepatic encephalopathy (SHE) is assumed to have a negative 
effect on patients' daily functioning, therefore treatment is recommended. 
However, no studies have been performed that document the clinical relevance 
of SHE. We performed a study in which the prevalence of SHE was determined 
in 100 outpatients with liver cirrhosis using three psychometric tests (Number 
Connection Tests part A and B, and the Symbol Digit Test) and automated EEG 
analysis. In addition, the influence of chronic liver disease on patients' daily 
functioning was assessed using the Sickness Impact Profile (SIP) questionnaire. 
The distribution of SIP scores of the patients with liver cirrhosis differed from 
the reference scores of the general population. Patients (n=32) with SHE had 
a worse SIP score (median score 8.3) than those (n=68) without SHE (median 
score 5) (p < 0.01). Multivariate analysis taking also into account age and 
severity of liver disease, showed that SHE independently was related to a 
diminished SIP score. The reproducibility of the SIP was high when the test 
was repeated after a 3-month period. We conclude that SHE implies impaired 
daily functioning and warrants attempt to treatment. Since not all patients with 
SHE had objective evidence of impaired daily functioning, routine treatment of 
SHE might not be justified. 
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INTRODUCTION 
Clinical manifestations of hepatic encephalopathy (HE) include a 
decreased intellectual function, personality disorders, an altered level of 
consciousness and neuromuscular dysfunction. I In addition to clinical manifest 
HE,2 a subclinical stage has been described, which cannot be detected through 
global clinical examination, but requires specific neuropsychological and 
neurophysiological examination.'-II The prevalence of subclinical hepatic 
encephalopathy (SHE) is estimated to vary from 23% to 41 % according to 
recent studies using appropiate methods. 12-" This variation in reported 
prevalence depends on the kind (psychometric or electrophysiologic) and 
number of tests used, and the population (etiology and severity of the liver 
disease) tested. 
SHE is considered to be clinically relevant for 2 reasons. Firstly, it could 
be a preceding stage of clinical manifest HE.3 However, this assumption is not 
proven as only one follow-up study" supports this concept. Secondly, the 
psychomotor deficits found in SHE could have a disadvanting influence on 
patients' daily functioning, for example in driving a car or at work. '6 In view 
of the reported high prevalence of SHE and its negative effect on daily life, 
routine screening of cirrhotic patients for SHE, and treatment of SHE is 
recommended. 17-1' However, the need of treatment of SHE is questionnable, as 
a recent study has shown that patients with SHE did not perform worse driving 
'on the road' than patients without SHE.20 Driving a car is an important, but 
small part of the total spectrum of daily activities. Therefore, on the basis of 
this study, no conclusions can be made about the effect of SHE on other aspects 
of daily functioning. 
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The influence of chronic diseases on daily life can be assessed using 
'Health-related Quality of life' questionnaires.21 The 'Sickness Impact Profile' 
(SIP) questionnaire, 22.23 is such an instrument for overall health assessment and 
has been used before to determine the influence of chronic liver disease on 
patients' daily functioning. 2'." 
The aim of the present study was to determine the prevalence of 
neuropsychological and neurophysiological defects in stable cirrhotic patients 
attending an university hospital outpatient clinic using a small neuropsychologic 
testbattery of three tests and the neurophysiological method of automated EEG 
analysis. The SIP questionnaire was used to determine the influence of SHE on 
daily functioning. In addition, the reproducibility of the SIP in cirrhotic patients 
was determined. 
PATIENTS AND METHODS 
Subjects 
From January I, 1992 to March I, 1995, 100 consecutive patients with 
histologically proven cirrhosis (n=99) and/or a surgical portosystemic shunt 
(n=3) attending the (out)patient clinic of Internal Medicine II and 
Hepatogastroenterology of the University Hospital Rotterdam-Dijkzigt were 
enrolled in the study. Exclusion criteria were clinical manifest HE, history of 
recent (less than 6 weeks) alcohol abuse, use of benzodiazepines and/or anti-
epileptics, inability to perform the psychometric tests and complete the SIP 
questionnaire due to insufficient knowledge of the Dutch language (e.g. foreign 
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labourers), and inability to perform the psychometric tests due to e.g. 
neurologic diseases or bad vision. All patients underwent a clinical and 
laboratory investigation, psychometric tests, and automated EEG analysis. In 
addition, the SIP questionnaire was administered. All examinations took place 
on the same day. Test-retest reliability of the SIP was assessed by re-
administering the questionnaire to patients without signs of decompensated liver 
disease (i.e. jaundice, ascites, encephalopathy, or variceal bleeding) after a 3-
month period. 
Clinical and laboratory assessment 
Mental state assessment included state of awareness; "Is the patient 
perfectly alert and well orientated in time, place, and person?". The level of 
attention (primary memory) and concentration was assessed by asking the 
patient to subtract serial sevens from 100 and to repeat a series of six 
nonconsecutive numbers in the same order (a normal individual can easily 
remember seven numbers forwards). Secondary memory (recent memory, new 
learning, encoding) was tested by asking the patient to remember three objects 
and to repeat these several minutes later. Remote memory (ability to recall 
events of weeks or years ago) was assessed by asking the patient about past 
presidents, dates of wars, and events that affect everyone. The Child-Pugh 
score was used to assess the severity of liver disease. 28 Three biochemical 
variables (serum albumin, bilirubin, and prothrombin time) in addition to the 
two clinical characteristics (presence or absence of ascites and encephalopathy) 
determine the Child-Pugh score. Each variable is given one to three points, 
leading to scores ranging from 5 (excellent liver function) to 15 points (poor 
liver function). 
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Neuropsychological assesment 
Number Connectioll Test part A alld B 
These tests are derivatives from the Trail Making Test>" and measure 
cognitive motor abilities. In the NCT part A patients have to connect numbers 
printed on paper consecutively from I to 25. Age dependent normal values of 
this NCT-A'o have been developed in 681 persons without liver disease." 
Normal values are expressed as the mean ± 2 standard deviations. In the NCT 
part B patients have to connect numbers from I to 13 and letters from A to L 
in alternating numerical and alphabetical order, ego I-A-2-B-3-C etc, requiring 
them to deal with 2 dimensions simultaneously. Age dependent normal values 
of this NCT-B have been developed in 237 healthy volunteers." After 
explanation, abbreviated demonstration tests were administered to be sure the 
patient had understood it. Errors were not enumerated, but patients were 
instructed to return to the preceding correct number or letter and then carryon. 
The test score is the time the patient needs to perform the test, including the 
time needed to correct the errors. A low score indicates a good performance. 
Symbol Digit Test 
This is a subtest of the Wechsler Adult Intelligence Scale (IN AIS) and 
measures motor speed and accuracy.33 The patient is given a list of symbols 
associated with digits from I to 9 and is asked to fill in blanks with numbers 
that correspond to each symbol. After explanation, an abbreviated 
demonstration test was administered to ensure that the patient understood the 
test correctly. The test score is the total number of correct sequential matchings 
of numbers to symbols in a 90-sec interval. A high score indicates a good 
performance. Data of 2169 Dutch and Belgian persons serve as a reference 
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group in the Netherlands. 34 A test result below the 2.5th percentile (i.e. the 
mean minus 2 standard deviations) is considered as abnormal. 
Neurophysiological assessment 
The EEG was recorded using standardized techniques while the patient, 
with the eyes closed, laid comfortably in a quiet room. When drowsiness 
occurred an auditory stimulus was applied by the EEG technician. Four 
electrodes were attached to the skin at the positions T3, T4, 01 and 02 
according to the international "10-20 system" . 35 Electrode impedance was kept 
lower than 5kO. After applying the usual bandpass filters (0.53 - 35 Hz) 2 runs 
of 100 seconds each were recorded and compared for reproducibility. Artefact 
free recordings were selected and fed into a computer after AD conversion 
(sample frequency 102.4 Hz). Ten epochs of 10 seconds each were analyzed by 
applying Fast Fourier Transformation and the mean power spectrum calculated. 
Patients are graded in the different stages of HE on account of their mean 
dominant frequency (MDF), and the relative powers of delta and theta activity. 
In a previous study36 we have validated this method in 51 healthy controls 
(median age 41 years, range 21 - 78) and 66 patients with cirrhosis of the liver 
(median age 60 years, range 21 - 75). A theta activity above 35% (i.e. the 
mean plus 2 standard deviations in controls) is considered abnormal 
Assessment of daily functioning 
The SIP questionnaire is an often used instrument that assesses the 
influence of disease and treatment on daily functioning. 22 The questionnaire 
consists of 136 items, which are grouped into twelve scales: sleep and rest, 
eating, work, home management, recreation and pastimes, ambulation, 
82 
Does SHE 'l/fecl daily jilllcliollillg? 
mobility, body care and movement (scores of the latter three may be combined 
as a physical subscore) social interaction, alertness behavior, emotional 
behavior, communication (scores of the latter four may be combined as a 
psychosocial subscore). Apart from a l2-dimensional profile score and the 
physical and psychosocial scores, the SIP provides the opportunity to compute 
a total score. Each score ranges from 0 (best score) to 100 (worst score). 
Patients mark only items that relate to their health at that time. The SIP has 
been translated and validated for the Dutch population. 37• 38 
Statistical analysis 
Wilcoxon's rank sum test or the Fisher Exact test were used to assess 
differences in clinical and laboratory characteristics between patients with and 
without SHE. Those variables reaching (borderline) statistical significance in the 
univariate analysis, were selected for multivariate analysis using multiple 
regression to determine their influence on patients' daily functioning. In this 
analysis SIP-scores were logarithmically transformed to reduce skewness of 
distributions. The limit for statistical significance was set at p = 0.05. 
Test-retest reliability (reproducibility) was assessed using intra-class 
correlation coefficients. Values above 0.7 generally are considered to indicate 
good reliability. 39 Internal consistency reliability of the SIP scales was assessed 
using Cronbach's alpha. 40 The internal consistency of a multi-item scale is a 
measure of the homogeneity of the items. An alfa of 0.70 is considered to 
demonstrate good internal consistency. 41 
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RESULTS 
One hundred consecutive patients with cirrhosis and/or portosystemic 
shunting (61 male, 39 female, mean age 50.9 years, SD 13, range 15-74) were 
screened for SHE. The etiology of the cirrhosis was chronic viral hepatitis in 
39 patients, alcohol abuse in 15 patients, and other causes (e.g. auto-immune, 
PBC, cryptogenic) in 46 patients. None of the patients had evidence of 
neurological and/or psychiatric abnormalities on global clinical examination 
performed in each patient by the same examiner (J.C.Q.). 
Figure 1 shows that the mean SIP scores of our patient population with 
liver cirrhosis were higher than normal reference scores of the general 
population.38 
Table 1 summarizes the prevalence of abnormality in age-corrected 
psychometric tests and automated EEG analysis found in our 
population. Thirtytwo patients had an abnormal automated EEG analysis (19 
patients) and/or one or more abnormal psychometric tests (19 patients). These 
32 patients were considered as having SHE, while the remaining 68 patients 
were considered not to have SHE. Clinical and laboratory characteristics of both 
patient groups are summarized in Table 2. The male/female ratio did not 
significantly differ between both groups. The same applied to the percentage of 
patients with alcohol abuse as etiology of the liver disease. There were 
significantly more patients with a Child-Pugh grade B or C in the patient group 
with SHE. In addition, there was a trend (p=0.08) towards a older age in the 
patients with SHE. 
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I---reference population +cirrhotic population I 
a bern rn eb si ab c w sr hrn rp e 
SIP scales 
Mean SIP scale scores in 100 patients with liver cirrhosis and a reference 
group of 594 Dutch persons. 38 
Abbrevations: a (ambulation), bCIll (bodycare and movement), m (mobility), 
eb (emotional behavior), si (social interactions), ab (alertness), 
c (communication), w (work), sr (sleep and rest), hm (home management), 
rp (recreation and pastimes), e (eating). 
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Table 1: Prevalence of abnormal neuropsychological and/or neurophysiological tests in 
100 cirrhotic patients without clinical signs of hepatic encephalopathy. 
Number Connection Test A 
Number Connection Test B 
Symbol Digit Test 
Automated EEG analysis 
percentage abnormal 
5 
18 
3 
19 
Table 2: Clinical and laboratory characteristics of cirrhotic patients with and without 
SHE. 
SHE -
(n ~ 68) 
Male/female ratio 40:28 
Age (years, median value + range) 51 (15-70) 
Child Pugh grade A:B/C ratio 57: 11 
Alcohol/non-alcohol ratio 59:9 
* Fisher Exact Test or Mann Whitney for age. 
SHE + 
(n ~ 32) 
21: 11 
55 (36-74) 
16: 16 
26:6 
p value' 
0.66 
0.08 
0.001 
0.55 
Functional impairment, defined as a total SIP score of at least 2.542 , was 
found in 88 % of the patients with SHE compared to 71 % in patients without 
SHE (p=O.07). 
Patients with SHE reported more impairment in several scales of the SIP than 
patients without SHE (Figure 2), reaching statistical significance only in the 
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'eating' scale and the total SIP score (Table 3). 
25 
I---without SHE +with SHE I 
20 
~ 15 § 
a.. 
iii 10 
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a bcm m eb si ab c w sr hm rp e 
SIP scales 
Figure 2: Mean SIP scale scores in 68 cirrhotic patients without SHE and 32 cirrhotic 
patients with SHE. 
Abbrevations: as in figure I 
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Table 3: SIP scores of cirrhotic patients with and without SHE. Scores are mininally 0 (good performance) and maximally 100 (bad performance). 
without SHE with SHE p value . internoJ nr.ofitems 
(n=68) (n=32) consistency' per scale 
~l:chQ~ciaI scal§ 
Social Interactions 4.7 (0 - 58.4) 9.5 (0 - 41.3) 0.13 0.71 20 
Alertness 8.2 (0 - 100) 4.1 (0 - 50.7) 0.89 0.85 10 
Emotional Behavior 0 (0 - 77.6) 0 (0 - 39.6) 0.08 0.70 9 
Communication 0 (0 - 40) 0 (0 - 45.9) 0.53 0.59 9 
Total psychosocial subscore 4.6 (0 - 54.2) 7.4 (0 - 32.3) 0.24 0.91 
Physical scales 
Ambul.tion 0 (0 - 22) 4.2 (0 - 50.8) 0.22 0.48 12 
Mobility 0 (0 - 28) 0 (0 - 65.6) 0.22 0.72 10 
Bodycare and movement 0 (0 - 14.5) 0 (0-36.1) 0.28 0.74 23 
Total physical subscore 0.4 (0-14.1) 1.6 (0 - 40.8) 0.15 0.87 
Ind~endent sca1~ 
Sleep!rest 11.8 (0 - 45.7) 12.2 (0 - 56.7) 0.12 0.40 7 
Work 0 (0-46.1) 16.2 (0-46.1) 0.07 0.60 9 
Home management 6.6 (0 - 31.6) 14.0 (0 - 75) 0.09 0.48 10 
Recreation and pastimes 10.2 (0 - 53.6) 10.2 (0 - 73.5) 0.53 0.46 8 
Eating 0 (0 - 18.7) 5.2 (0 - 19.7) 0.01 0.26 9 
Total SIescm:.e 5 (0 - 31.8) 8.3 (0 - 29.8) 0.01 0.92 137 
Median scores are given, r?.nge between brackets. Statistics: • Wilcoxon's rank sum test, /I Cronbachs ex (pooled data) 
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Possible confounders in these findings could be age and the severity of 
liver disease, as patients with SHE tended to be older and had a more severe 
liver disease as compared to those without SHE (Table 2). Therefore, SHE, age 
and the Child-Pugh classification were selected for multivariate analysis to 
analyse their impact on the SIP. This analysis showed that both age and Child-
Pugh classification, in addition to SHE, did not significantly affect the total SIP 
score. 
The results of the SIP scores were similar between the various etiologies 
of the chronic liver disease. Patients with alcoholic cirrhosis and chronic viral 
hepatitis reported only more impairment on the physical subscore of the SIP as 
compared to non-viral and non-alcoholic cirrhotics (data not shown). 
Reliability testing of the SIP questionnaire in our patient population using 
internal consistency measures showed that 7 subscales of the SIP fell below the 
recoflUnended a-coefficient of 0.70 (Table 3). This suggests that the items of 
these SIP scales are not homogeneous in the population of patients with liver 
cirrhosis; i.e. the items of such a scale do not reliably represent an underlying 
characteristic.4' The high internal consistency of the total SIP score is at least 
partly attributable to the high number of items. 
The reproducibility of the SIP questionnaire was high as we found a good 
correlation between the SIP results in a 3-month interval (Table 4). Minor, 
statistically not significant, differences of median SIP scores were found 
between the first and second completed SIP questionnaire, indicating that during 
the 3 months patients had not systematically changed with regard to the SIP 
questiommire. 
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Table 4: SIP scores of 38 cirrhotic patients at baseline and after 3 months. 
t = o months t = 3 months p value . Intra-class correlation 
~chQ~cia1 ~caI~ 
Social Ioteractions 7.4 (0 - 48.5) 5.9 (0 - 35.3) 0.82 0.84 
Alermess 3.8 (0 - 66.5) 0 (0 - 74.5) 0.46 0.89 
Emotional Behavior 0 (0 - 68.7) 0 (0 - 48.5) 0.77 0.81 
Communication 0 (0 - 52.4) 0 (0 - 52.4) 0.87 0.82 
Total psychosocial subscore 5.6 (0 - 44.3) 4.8 (0-42.7) 0.56 0.94 
Physica] scales 
Ambulation 0 (0 - 35.2) 0 (0 - 39.3) 0.69 0.88 
Mobility 0 (0 - 46.6) 0 (0 - 34.6) 0.85 0.58 
Bodycare and movement 0 (0 - 18.0) 0 (0 - 18.2) 0.99 0.88 
Total physical subseore 1.3 (0 - 23.4) 1.8 (0 - 42.7) 1.0 0.89 
Indenendent ~cales 
Sleep!rest 10.9 (0 - 73.5) 4.9 (0 - 56.7) 0.56 0.83 
Work 13.3 (0 - 46.1) 10.5 (0-46.1) 0.67 0.89 
Home management 6.6 (0 - 41.3) 6.6 (0 - 44.9) 0.53 0.67 
Recreation and pastimes 4.3 (0 - 63.7) 8.2 (0 - 54.0) 0.88 0.67 
Eating 0 (0 - 18.7) 0 (0 - 19.6) 0.25 0.58 
Total SIP score 5. 5 (0 - 32.3) 5.6 (0 - 30.7) 0.68 0.96 
Median scores are given~ range between brackets. Statistics: ~Wilcoxon's rank sum test 
Does SHE affeci daily filllCliollillg? 
DISCUSSION 
We performed a study to determine the influence of SHE on the Quality 
of Life. Three psychometric tests with age-specific normal values (NCT -A and 
B, SDT) and automated EEG analysis were selected to be used as a 
neuropsychological and neurophysiological screen for SHE. We defined SHE 
as at least one abnormal psychometric test and/or automated EEG analysis. 
Using this (arbitrary) definition we found a SHE prevalence of 32 % in our 
outpatient cirrhotic population, which is in agreement with the prevalence found 
in studies using the same methods. 12-14 
The clinical relevance of SHE in our population was not obvious as these 
patients do not show mental or neurological abnormalities on clinical 
examination. Furthermore, according to the patients themselves and their 
spouses, the majority of these patients seemed to function well in their social 
environment and at work. We used the SIP as a method for evaluating the 
influence of SHE on daily functioning in cirrhotic patients as this questionnaire 
contains items which resemble the complaints seen in early stages of HE (Table 
5). In addition, this questionnaire has been used in a previous study in patients 
with SHE.ID 
In our study we found a diminished level of functioning in patients with 
SHE. Interestingly, patients with SHE showed a trend towards significant 
impairment of those activities (e.g. work, home management) which are 
expected to be affected in cognitive disorders. Although age and severity of 
liver disease could have influenced the results, multivariate analysis showed that 
they did not significantly affect the total SIP score. 
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Table 5: Example of items of the Sickness Impact Profile which resemble conditions 
seen in patients with early stages of hepatic encephalopathy 
Scale 
Sleep and rest 
Emotional behavior 
Bodycare and movement 
Home management 
Mobility 
Social Interactions 
Ambulation 
Alertness 
Communication 
Work 
Recreation and pastimes 
Eating 
Item 
I am sleeping or dozing most of the time - day and 
night 
I act nervous or restless 
I have trouble getting shoes, socks, or stockings on 
I have difficulty doing handwork, e.g. turning faucets, 
using kitchen gadgets, sewing, carpentry 
I am staying in bed most of the time 
I am doing fewer social activities with groups of 
people 
I walk more slowly 
I react slowly to things that are said or done 
I have trouble writing or typing 
I do not do my job as carefully and accurately as 
usual 
I am doing more inactive pastimes in place of my 
other usual activities 
I am eating special or different food, e.g. soft food, 
bland diet, low-salt, low-fat, low-sugar 
How reliable are our findings? Firstly, our study was performed in a 
sample of appropriate size (n = 100), which makes the results of the SIP more 
adequate for statistical analysis. Secondly, SHE was diagnosed using a 
combination of psychometric and electrophysiological tests, which is in 
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accordance with the established definition of SHE (i.e., neuropsychologic and 
electrophysiologic defects in patients with no clinical signs of hepatic 
encephalopathy). Furthermore, we only used validated psychometric tests with 
age-adjusted normal values, thereby abolishing the diagnostic bias caused by 
aging on neuropsychological performance. 14 Thirdly, we used a validated test 
to evaluate daily functioning, with reference values for the Dutch population. 
In addition, we found a good test-retest reliability of the SIP in our patient 
population with liver cirrhosis. 
How logical are our findings? Patients with hepatic encephalopathy grade 
1 can complain about e.g. sleep disturbances, impaired calculation, shortened 
attention, mild personality changes and muscular incoordination.44 Patients with 
SHE (in literature considered as a preclinical stage of hepatic encephalopathy) 
should therefore, although to a lesser extent, have similar complaints in daily 
life. Indeed, our results showed that patients with SHE complained more than 
patients without SHE in SIP scales such as sleep and rest, work, emotional 
behavior and home management (all borderline significant). The finding that 
patients with SHE differed significantly in the SIP categorie 'eating' than 
patients without SHE can be explained by the fact that patients with SHE had 
a more severe liver disease (Table 2), and therefore had more often a salt or 
protein restricted diet. 
Should we treat patients with SHE because of the diminished level of daily 
functioning found in this study? Up to now, no intervention studies have been 
performed, in which functional status is used as an outcome of treatment 
efficacy in SHE. Treatment of SHE could be beneficial in patients with stable 
liver disease and impaired performance at work or daily life. We, therefore, 
strongly suggest the use of 'health-related quality of life questionnaires' in trials 
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with treatment specifically directed to SHE. In addition, due to the low internal 
consistency of several subscales of the SIP, other' quality of life questionnaires' 
should be evaluated. 
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DOES A LOW-DOSE OF LACTULOSE IMPROVE QUALITY OF 
LIFE IN PATIENTS WITH LIVER CIRRHOSIS? 
The contents of this chapter are in press in: 
Advances in hepatic encephalopathy and metabolic nitrogen exchange, Record 
CO (Ed), CRe Press Boca Raton, USA 1996 under the same title with the 
following authors: I.e. Quero, M. Groeneweg, J. Meulstee, w.e.J. Hop, 
S.W. Schalm 

Does lac/ulose improve Quality of Life ill cirrhosis? 
ABSTRACT 
Treatment of subclinical hepatic encephalopathy (SHE) is recommended 
with the aim to improve daily functioning. However, no studies have been 
performed which document an improved quality of life after treatment. The aim 
of this study was to determine the efficacy of a low dose of lactulose (30 grams 
daily) on psychometric tests (NCT-A, SOT), spectral-EEG, and quality of life. 
A 6-months double-blind placebo controlled study was performed in 40 
consecutive stable cirrhotic patients (29 male, mean age 51 years, 33 Child-
Pugh grade A), who had elevated arterial ammonia levels at baseline. Quality 
of life was assessed using the Sickness Impact Profile (SIP) questionnaire. 
There were 4 drop-outs (2 in the lactulose group) during the treatment period 
(2 side effects, 1 progression into HE, 1 not associated with the trial 
medication). No significant changes were seen after treatment in the arterial 
NH3, psychometric tests, EEG and total SIP score in both the lactulose and 
placebo group. We conclude that a low-dose lactulose treatment in cirrhotic 
patients is not effective with respect to ammonia, psychometric tests, EEG and 
quality of life. Whether patients with SHE and impaired quality of life will 
benefit from effective treatment (higher lactulose dose?) remains to be 
determined. 
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INTRODUCTION 
Hepatic encephalopathy (HE) refers to neuropsychiatric abnormalities due 
to liver insufficiency. Traditionally, HE is clinically graded in four stages of 
severity ranging from abnormal behaviour to unresponsive coma. 1 
In addition to the clinical grading of HE, a subclinical stage has been 
described in which patients with cirrhosis, regardless of its etiology, 
demonstrate a number of quantifiable neuropsychological defects, yet have a 
normal mental and neurological status on global clinical examination.2 
Psychometric tests as well as neurophysiological tests can be used for 
diagnosing subclinical hepatic encephalopathy (SHE). 3 The prevalence of SHE 
has been reported to vary from 30%4 to 84 %.5 The main reasons for such a 
wide variation in frequency are the lack of uniformity in the application of 
diagnostic tests, and the differences in the patient population.6 
The perceptual-motor and visuopractic deficits found in SHE could have 
implications in performing routine activities (e.g. driving an automobile, doing 
manual tasks), especially in those patients working in mechanical and skilled 
occupations.7-9 
Due to the high prevalence of SHE and its possible impact on daily life, 
treatment of SHE with ammonia lowering agents is recommended. 10 Intervention 
studies have been performed with non-absorbable disaccharides,l1-13 protein 
restriction,14 and branched chain amino acids. 8. 15 In these intervention studies 
psychometric tests and EEG showed improvement after treatment, which 
suggests that SHE is reversible and of metabolic origin. However, it is unclear 
whether these treatment regimens also lead to an improved daily functioning. 
The aim of this study was to determine whether a low dose of crystalline 
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lactulose improves neuropsychological and electrophysiological functioning in 
patients with liver cirrhosis. In addition, we wanted to assess whether this 
improvement would also result in an improvement of patients' daily functioning. 
PATIENTS AND METHODS 
Subjects 
From October 1, 1992 to August 31, 1994,40 consecutive biopsy-proven 
cirrhotic patients (29 male, mean age 50.8 years, SD 14, range 24-70, 33 
Child-Pugh grade A, 6 grade B, 1 grade C) without any clinical signs of HE, 
and with elevated arterial ammonia levels attending the outpatient clinic of 
Internal Medicine II and Hepatogastroenterology of the University Hospital 
Rotterdam-Dijkzigt were entered into the study. The etiology of the cirrhosis 
was chronic viral hepatitis in 12 patients, alcohol abuse in 11 patients, and other 
causes (e.g. auto-immune, PBC, cryptogenic) in 17 patients. None of the 
patients received treatment for hepatic encephalopathy on entry into the study. 
Patients with clinical signs of HE, unstable liver disease, a history of recent 
alcohol abuse (less than 6 weeks), use of benzodiazepines and/or anti-epileptics 
were excluded from the study. On entry into the study, patients received a full 
examination, including a neurological examination, laboratory investigation, 
psychometric tests and spectral EEG. In addition, patients' daily functioning 
was assessed. All examinations were performed on the same day. At the onset 
of the trial, none of the patients had evidence of neurological and/or psychiatric 
abnormalities on global clinical examination performed in each patient by the 
same examiner (J.C.Q.). All patients had an elevated arterial ammonia level 
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(i.e., more than 30 "molll) at baseline measured with Dupont aca procedure. 16 
Neuropsychological assesment 
Number Connection Test 
This test is a derivative from the Trail Making Testl7 and measures 
cognitive motor abilities. In the NeT subjects have to cOlmect numbers printed 
on paper consecutively from 1 to 25, as quickly as possible. Errors are not 
enumerated, but patients are instructed to return to the preceding correct 
number and then carryon. The test score is the time the patient needs to 
perform the test, including the time needed to correct the errors. A low score 
indicates a good performance. 
Symbol Digit Test 
This is a subtest of the Wechsler Adult Intelligence Scale (W AIS) and 
measures motor speed and accuracy." The patient is given a list of symbols 
associated with digits from 1 to 9 and is asked to fill in blanks with numbers 
that correspond to each symbol. The test score is the total number of correct 
sequential matchings of numbers to symbols in a 90-sec interval. A high score 
indicates a good performance. 
After explanation of each psychometric test, an abbreviated demonstration 
test was administered to ensure that the patient understood the test correctly. 
Electrophysiological assessment 
The EEG was recorded using standardized techniques (Nihon Kohden) 
while the patient, with the eyes closed, laid comfortably in a quiet room. When 
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drowsiness occurred an auditory stimulus was applied by the EEG technician. 
Four electrodes were attached to the skin at the positions T3, T4, 01 and 02 
according to the international "10-20 system". 19 Electrode impedance was kept 
lower than 5kn. After applying the usual bandpass filters (0.53 - 35 Hz) 2 runs 
of 100 seconds each were recorded and compared for reproducibility. Artefact 
free recordings were selected and fed into a computer after AD conversion 
(sample frequency 102.4 Hz). Ten epochs of 10 seconds each were analyzed by 
applying Fast Fourier Transformation and the mean power spectrum calculated. 
Patients are graded in the different stages of HE on account of their mean 
dominant frequency (MDF) , and the relative powers of delta and theta 
activity.20 
Assesment of daily functioning 
The SIP questiol1llaire is an instrument that assesses the influence of 
disease and treatment on daily functioning.'1 The questiol1llaire consists of 136 
items, which are grouped into twelve categories: sleep and rest, eating, work, 
home management, recreation and pastimes, ambulation, mobility, body care 
and movement (scores of the latter 3 may be combined as a physical subscore) 
social interaction, alertness behavior, emotional behavior, communication 
(scores of the latter 4 may be combined as a psychosocial subscore). Apart the 
physical and psychosocial scores, the SIP provides the opportunity to compute 
a total score. Each score ranges from 0 (best score) to 100 (worst score). 
Patients mark only items that relate to their health at that time. The SIP has 
been translated and validated for the Dutch population. 22 
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Study design 
Patients were randomized consecutively to the lactulose or treatment 
group by a numbered randomization list supplied by the study sponsor after all 
entry data were completed. Crystalline lactulose sachets (containing 10 g 
crystalline lactulose) and matched placebo (containing lactose) sachets were 
kindly supplied by the study sponsor. 
All patients started with a dose of 109 lactulose/placebo daily, which was 
gradually increased to 10 g lactulose/placebo three times a day after one week. 
This dose was to be maintained until the end of the treatment period. In case 
diarrhoea occured, the daily dose was decreased by 10 g lactulose/placebo and 
maintained until the end of the treatment period. Patients were seen at monthly 
intervals to assess acceptability of treatment. In addition, arterial ammonia 
concentration, psychomotor performance, spectral EEG and patients' daily 
functioning was assessed at 3-monthly intervals. Lactulose/placebo was stopped 
after 24 weeks of treatment. Three months after treatment, a complete 
evaluation was performed in each patient, including arterial ammonia 
measurement, psychomotor performance, spectral EEG and daily functioning. 
The study protocol was approved by the Medical Ethical Committee of 
the University Hospital Rotterdam. Written informed consent was obtained from 
all patiens in accordance with the EEC guidelines on Good Clinical Practice, 
which underwrites the principles of the Declaration of Helsinki, as most 
recently revised in Hong Kong, 1989. 
Statistical analysis 
To assess the similarity of the two groups at randomization, a number of 
clinical and laboratory characteristics were compared using the Chi' and 
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Wilcoxon's rank sum test. The main objective was to compare changes in the 
arterial ammonia concentration, spectral EEG, psychomotor performance and 
daily functioning at the end of treatment. Changes within treatment groups were 
evaluated using Wilcoxon's signed rank test. Wilcoxon's rank sum testing was 
performed to assess the difference in the graded response in the various 
parameters of SHE between both treatment groups. The limit for statistical 
significance was set at p = 0.05. 
RESULTS 
Patient characteristics at randomization are summarized in Table 1. 
Patients in the lactulose and placebo group appeared well matched for the major 
entry characteristics. 
Table 1: Patient characteristics (mean ± standard deviation) on entry into the study 
lactulose grou(2 121acebo grou!! 
number of patients 19 21 
age (years) 51.9 ± 13 49.7 ± 12 
Male : female 14 : 5 15 : 6 
Child Pugh A : B : C 14 : 4 : 1 19: 2 : 0 
arterial NH3 (llmolll) 68.6 ± 24 68.1 ± 32 
NCT (seconds) 30.3 ± 11 37.3 ± 13 
SDT (points) 46.8 ± 13 45.8 ± 16 
EEG: MDF 9.2 ± 1 8.8 ± 1 
EEG: % theta 21.3 ± 16 28.9 ± 23 
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Forty patients with liver cirrhosis and an elevated arterial ammonia 
concentration entered the study. Four of the 40 patients entered into the trial did 
not complete the treatment period. Two patients (1 in the lactulose group, 1 in 
the placebo group) dropped out of the study due to development of diarrhoea; 
one patient (placebo group) due to development of HE and one patient (lactulose 
group) due to personal reasons not associated to the study. Of the remaining 36 
patients who completed the treatment period, one patient died due to a 
gastrointestinal bleeding and one underwent a liver transplantation (both in the 
lactulose group) during the post-treatment survey period. 
During treatment flatulence occured in 17 patients (8 patients in the 
lactulose group, 9 in the placebo group). Ten patients (5 patients in each 
treatment group) had severe diarrhoea; the lactulose dosage had to be lowered 
to 20 grams daily in 3 patients, and to 10 grams daily in 1 patient. 
The effects of treatment are summarized in Tables 2 and 3 (per protocol 
analysis). Neither in the lactulose group, nor in the placebo group significant 
changes were found in the arterial ammonia levels, psychometric tests and 
spectral EEG after 24 weeks of treatment (Table 2). Also the changes in 
response in these parameters did not significantly differ between lactulose and 
placebo. A significant improvement in the NCT score was seen in the placebo 
group, but not in the lactulose group. However, the change in the NCT 
performance after treatment was not significantly different (p = 0.22) between 
lactulose and placebo, when adjusted for baseline values. Patients' daily 
functioning, as measured with the SIP, also did not change at the end of the 
treatment period (Table 3). A significant improvement in the lactulose as well 
as in the placebo group was seen in the psychosocial subscore of the SIP. 
However, the difference in the changes of the psychosocial subscore of the SIP 
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after treatment was not significant between the lactulose and placebo group. 
Similar results were obtained when intention to treat analysis was performed 
(data not shown). 
Table 2: Biochemical, neuropsychological and electrophysiological parameters of SHE 
(mean ± standard deviation) of the patients who completed the study at 
baseline and at the end of the treatment (months). 
lactulose group placebo group 
t = 0 t = 6 t = 0 t = 6 
NH, (I'molll) 70.4 ± 24 69.2 ± 26 66.8 ± 33 70.8 ± 27 
NeT (seconds) 29.2 ± 11 28.3 ± 11 37.4 ± 14 30.0 ± 8' 
SDT (points) 46.7 ± 14 49.3 ± 19 46.2 ± 17 49.7 ± 19 
EEG: MDF 9.2 ± 1.1 9.0 ± 1.5 8.8 ± 1.2 8.8. ± 1.0 
EEG: % theta 21.6 ± 17 21.0 ± 16 28.8 ± 24 27.2 ± 23 
• P < 0.005 
Table 3: Social parameters of SHE (mean ± standard deviation) of the patients who 
completed the study at baseline and at the end of the treatment (months). 
Jactylose group 
t = 0 
Psychosocial SIP score 13.8 ± 15 
Physical SIP score 2.9 ± 4 
Total SIP score 8.8 ± 9 
• p < 0.05, # p < 0.01 
t = 6 
9.9 ± 13' 
4.5 ± 5 
7.9 ± 8 
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placebo group 
t = 0 
10.3 ± 12 
2.5 ± 3 
8.7 ± 7 
t = 6 
9.0 ± 12' 
3.0 ± 4 
8.0 ± 8 
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DISCUSSION 
This study is among the first to study the effect of lactulose on the quality 
of life in patients with liver cirrhosis. Patients were treated for 6 months to 
assess acceptability of a chronic treatment for improving quality of life. 
Preselection of the patients was only made on the basis of an elevated arterial 
ammonia, as lowering of the ammonia concentration is a main objective in the 
treatment of HE?' In order to prevent side effects, we chose a low dose of 
lactulose. However, even with this low dose, 65% of the patients in the 
lactulose group experienced flatulence or diarrhoea; only one patient in this 
group had to be withdrawn from the study due to severe diarrhoea. 
No effect of treatment was seen on the arterial ammonia concentration, 
psychometric tests, and spectral EEG. In the placebo group, NCT performance 
showed an improvement after 24 weeks, which could be explained by a 
learning-effect. In addition, treatment did not result in an improvement in 
patients' daily functioning as measured with the SIP. 
Can we conclude from our results that treatment of SHE does not lead to 
an improved quality of life? There are several reasons why this conclusion can 
not be drawn from our results. 
Firstly, the lactulose dose used by us could have been too low as no 
significant lowering of the arterial ammonia concentration was detected after 6 
months of treatment. Secondly, no preselection was made on the basis of 
abnormal psychometric tests and spectral EEG. One could assume that 
improvement of the biochemical, neuropsychological, and electrophysiological 
markers of SHE is a prerequisite for improving quality of life in these patients. 
Whether cirrhotic patients with SHE will benefit from chronic lactulose 
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treatment remains to be determined. We, therefore, propose to perform future 
intervention studies with higher doses of lactulose, and only in patients with 
definite SHE and an impaired quality of life. 
AcknolVledgemellls: 
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THE EFFECT OF HELICOBACTER PYLORI ERADICATION 
ON THE ARTERIAL AMMONIA LEVELS IN 
PATIENTS WITH LIVER CIRRHOSIS 
The contents of this chapter have been published in a short version in: 
The Lancet (1995, 346: 713-714) under the title Hyperammonaemia and 
Helicobacter pylori with the following authors: J.C. Quero, 
!.J.C. Hartmann, F.W.M. de Rooij, J.H.P. Wilson, S.W. Schalm 

Hyperammonaemia and H pylori 
ABSTRACT 
Helicobacter pylori (H pylori) infection in patients with liver cirrhosis 
could be a risk factor for hepatic encephalopathy (HE), as H pylori produces 
large amounts of ammonia (NH3) in the stomach. The aim of this study was 
to determine the effect of H pylori eradication on the blood ammonia level in 
patients with liver cirrhosis. In 63 consecutive biopsy-proven cirrhotic 
patients H pylori status was determined using the 14C-urea breath test. In 
addition, fasting arterial NH3 was determined. 
Eleven patients with hyperammonaemia and H pylori infection were treated 
with omeprazole 40 mg daily and amoxycillin 500 mg four times daily for 2 
weeks. Only one patient had not eradicated H pylori 2 months after 
treatment. H pylori eradication resulted in a significant reduction (p < 0.05) 
of baseline blood NH3 levels from 79.3 "mol/l (SD 27, range 55-141) to 
63.5 "moIlI (SD 27, range 27-121). Ten weeks after treatment the mean 
blood NH3 level had risen to 78.7 "moIlI (SD 24, range 46-131), which was 
not significantly different from baseline values. 
We conclude that H pylori eradication does not result in a long-term 
reduction of blood ammonia levels in hyperammonaemic patients with 
cirrhosis. Reduction of NH3 after treatment can be explained by the non-
specific effect of amoxycillin on ammonia-producing gut flora, rather than by 
the eradication of the ammonia-producing H pylori itself. 
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INTRODUCTION 
Neurotoxic substances originating from the gut and bypassing the liver 
are believed to play a major role in the pathogenesis of hepatic 
encephalopathy. Some of the substances claimed to have a neurotoxic effect 
are ammonia, GABA, endogeneous benzodiazepines, tryptophane and 
glutamate. 1.2 As none of these substances fully accounts for the development 
of HE, the pathogenesis of HE is believed to be multifactorial.3 However, 
the ammonia hypothesis provides the strongest evidence as: I) elevated 
arterial ammonia levels are frequently found in HE, 2) ammonia loading 
tests can cause HE in patients with cirrhosis of the liver or with a porto-
caval shunt, 3) improvement of HE can be achieved with agents lowering the 
arterial ammonia level. I 
Therapy of HE should focus on two aspects: amelioration of liver 
function, for instance by elimination of the etiologic factor, and secondly the 
therapy of HE itself. Until now the most effective therapy of HE is lowering 
of the blood ammonia by reducing the ammonia production of the colonic 
flora with either non-absorbable disaccharides, antibiotics or protein 
restriction.' 
However, the colon is not the only part of the gastro-intestinal tract 
where ammonia is generated. Ammonia is also being produced in large 
quantities in the stomach of persons infected with Helicobacter pylori (H 
pylori).5-7 
H pylori is a spiral-shaped bacterium, which is often found in the 
gastric mucosa of patients with antrum gastritis and lor duodenal ulcer and is 
believed to play a major role in the pathogenesis of these diseases. 8-12 The 
118 
Hyperallllllollaemia alld H pylori 
assessment of the endogeneous urease activity of H pylori allows a simple 
and non-invasive detection of this micro-organism. "·1. 
As far as we know, no studies have been published with respect to the 
contribution of gastric ammonia production by H pylori to the total ammonia 
production in the gastro- intestinal tract. If this contribution is significant, H 
pylori-positive patients with liver cirrhosis could be at a higher risk of 
developing HE than H pylori-negative patients. 17•2• Recently, H pylori has 
indeed been named as a risk factor for HE. 21 Therefore, eradication of H 
pylori could be indicated for H pylori-positive patients with liver cirrhosis in 
order to treat or prevent episodes of HE. Several treatment regimes are being 
used for the eradication of H pylori.22 A combination therapy of tripotassium 
dicitrato bismuthate (bismuth), amoxycillin and metronidazole is 
recommended, however, newer treatment regimes have proven efficacy with 
less side effects.23 -28 
The aim of the present study was to determine the effect of H pylori 
eradication on the arterial ammonia concentration in patients with liver 
cirrhosis. 
PATIENTS AND METHODS 
Subjects 
From April 1, 1994 to May 31, 1995, 63 consecutive biopsy-proven 
cirrhotic patients (mean age 50 years, SD 14, range 18-70) attending the 
(out)patient clinic of Internal Medicine II and Hepatogastroenterology of the 
University Hospital Rotterdam - Dijkzigt were screened for the presence of 
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H pylori by a "C-urea breath test. In addition, the fasting arterial ammonia 
concentration was determined in each patient. 
Subsequently, H pylori-positive patients with elevated arterial ammonia 
levels (defined as more than 50 !{molll) received a combination therapy of 
omeprazole 40 mg daily and amoxycillin 500 mg four times daily for 2 
weeks. Patients with unstable liver disease (Le. over a period of 6 weeks 
prior to entry variations in medication and/or liver function tests (bilirubin, 
albumin, prothrombin time)) and those receiving treatment with lactulose or 
neomycin were excluded from this intervention study. 
At the end of treatment fasting arterial ammonia level was determined. 
Ten weeks after the discontinuation of treatment patients received the final 
evaluation, consisting of a "C-urea breath test and a fasting arterial ammonia 
determination. 
Laboratory assessments 
Ammonia determination 
Arterial blood was drawn in the morning in the fasting patient. A 
puncture was performed in the radial artery in the hyperextended wrist using 
a 2.0 ml heparinized syringe. After drawing blood the syringe was gently 
rotated and immediately placed on crushed ice. Ammonia measurements 
were performed within 15 minutes after puncture using the Dupont aca 
procedure (Dimension SMS) (Dupont de Nemours; Wilmington, DE).2. 
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14C-urea breath test 
The 14C-urea breath test was performed in the morning in the fasting 
patient according to the method described by Rauws et al. 15 In summary, 
patients ingested a liquid test meal containing 110 kBq 14C-urea. Breath 
samples were collected at baseline, and after 50 and 60 minutes. Patients 
were considered to be infected with H pylori when breath radioactivity was 
more than 0.07% of the administered 14C dose/mmol expired CO2 multiplied 
by bodyweight in kilograms. 
Statistics 
Wilcoxon's signed rank test was performed to assess the difference in 
arterial ammonia concentration before and after H pylori eradication therapy. 
Ethics 
This study was an investigator initiated study, and performed in 
accordance with the EEC guidelines on Good Clinical Practice, which 
underwrites the principles of the Declaration of Helsinki, as most recently 
revised in Hong Kong, 1989. The study protocol was approved by the 
Medical Ethical Committee of the University Hospital Rotterdam - Dijkzigt. 
Patients were required to give their written informed consent before entering 
the study. 
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RESULTS 
Thirtytwo (51 %) out of 63 cirrhotic patients were infected with H 
pylori, as determined with the 14C-urea breath test. Nineteen (59%) of these 
H pylori-infected patients had an elevated fasting arterial ammonia 
concentration, of which 13 patients entered the intervention study with 
omeprazole and amoxycillin. No side effects (diarrhoea, stomatitis, allergic 
exanthema) occured during the 2 weeks treatment. 
Fasting arterial ammonia concentration decreased in the 13 patients 
from 87.0 pmolll (SD 36, median 70, range 55-170) to 70.3 pmolll (SD 30, 
median 65, range 27-124) after 2 weeks of treatment (p=O.OI). 
Two patients were withdrawn from the study in the posttreatment 
phase as they underwent a liver transplantation. 
In only one of the 11 remaining evaluable patients treatment did not 
result in eradication of H pylori. The effect of therapy on the blood ammonia 
levels in the 10 patients who eradicated H pylori are shown in Figure 1. 
These 10 patients had a mean fasting arterial ammonia concentration of 79.3 
pmolll (SD 27, median 70, range 55-141) at baseline. After two weeks of 
treatment the mean fasting arterial ammonia concentration was reduced to 
63.5 pmolll (SD 27, median 62, range 27-121; p=0.02). Ten weeks after 
treatment the mean fasting arterial ammonia concentration in all patients had 
risen to 78.7 pmolll (SD 18, median 82, range 46-107). This ammonia 
concentration did not differ significantly from baseline. 
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Figure 1: 
o 2 12 
study period (weeks) 
The effect of 2 weeks ollleprazole 40 Illg daily and allloxycillin 500 Illg 
four times daily on the fasting arterial ammonia concentration in 
hyperanunonaelllic patients who eradicated Helicobacter pylori. 
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DISCUSSION 
A possible role of gastric ammonia production in the pathogenesis of 
HE was already described in 1959.17 Recently, the effect of eradication of H 
pylori on blood ammonia levels in 2 patients with HE has been described by 
Ito et a!. 30 The authors suggested that the persistently lowered blood 
ammonia levels 5 months after therapy could only be explained by the 
absence of H pylori as the colonic flora should have been restored after this 
period. Prior to performing our study, we also experienced a remarkable 
improvement in one of our patients with HE after eradicating his H pylori 
infection with a combination therapy of metronidazole, bismuth and 
amoxycillin (the same antibiotics used in Ito's first patient). However, other 
mechanisms besides H pylori eradication might have been responsible for 
this effect. 31 
Our data confirm a fall in blood ammonia with eradication therapy of 
H pylori, but question whether this fall is due to eradication of ammonia-
producing H pylori. The return of blood ammonia levels 2 months after 
therapy to baseline values in patients with eradication of H pylori suggests a 
non-specific effect of antibiotics rather than an effect of eradication of the 
organism. Our observations have been confirmed by Plevris et al,32 who did 
not find a significant effect of H pylori on the blood ammonia level 2 hours 
after oral urea administration. 
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Chapter 7 
SUBCLINICAL HEPATIC ENCEPHALOPATHY: DIAGNOSIS, 
CLINICAL IMPLICATIONS, AND UPDATE ON INTERVENTION. 
A DISCUSSION 

Discussioll 
Subclinical hepatic encephalopathy (SHE) is a real, but rather mysterious 
entity for physicians, who deal with patients with liver cirrhosis. 
The first problem a physician, who decides to screen patients for this 
entity, has to solve is which diagnostic methods he should use, as there is no 
"gold standard" diagnostic test. I The long list of diagnostic tests for the 
detection of SHE mentioned in the literature has caused this confusion.2 Most 
authors propose the use of psychometric tests, because these are cheap, simple 
to perform, easy to interpret, and have a reported high sensitivity. However, 
the performance and interpretation of psychometric tests is not as simple as 
usually suggested. 
Firstly, performance should be strictly standardized for proper intra- and 
interpatient comparison. Attention should always be paid to the lighting of the 
room, the vision of the patient (does he wear his reading glasses?), the sitting 
position, the materials used (appropriate pencil?), chronometry, and the scoring 
of the test. 
Secondly, normal values should be available for each test. Even simple 
psychometric tests, such as the Number Connection Test part A (NCT-A), 
should be adjusted for age.3 When a more complicated test, such as the Number 
Connection Test part B (NCT -B) that requires adequate knowledge of the 
alphabet, is selected, additional adjustment of normal values is required as its 
result is highly dependent on the education level of the patient. 4 In addition, 
normal values developed in one country should not be used in a patient 
popUlation of another country. Furthermore, NCT forms supplied by a single 
company might be different. 5 
In summary, the use of a psychometric test in clinical practice requires the same 
attention to performance, normal values and quality control as is widely 
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accepted for biochemical tests. 
Are psychometic tests, when correctly executed, alone sufficient for 
detecting SHE? Probably not, since overlap between abnormal psychometric test 
results and abnormal neurophysiological (EEG or evoked potentials) test results 
is pOOr.4• 6 This observation suggests that these two different groups of test 
methods measure different components of cerebral impairment. Therefore, 
psychometric tests, as well as neurophysiological tests should both be used for 
the detection of SHE. The advantage of neurophysiological tests is that they are 
not influenced by age and educational background. Obvious disadvantages of 
these tests are the need for sophisticated, expensive equipment, and well-trained 
personnel. As in psychometric tests, standardization of the neurophysiological 
test performance is important. Carefull attention should be payed to the 
cooperation of the patient (required in visual and P300 evoked potentials) and 
to the wakefulness of the patient (required in spectral EEG). Probably the 
digestive state in which these tests are performed should also be standardized, 
as outcome may be affected by ingestion of a meal.7 
Once the diagnostic tests have been performed, and a patient with SHE 
is identified, the physician is confronted with a second problem: What is the 
clinical significance of SHE? 
The main characteristic of SHE is that practical abilities (Le., functional 
performance) are impaired, while verbal abilities are maintained. This 
phenomenon has been explained by dividing human abilities in "crystallized" 
intelligence and "fluid" intelligence. 8 Crystallized intelligence plays a role in 
logical, and mathematical thinking. It consists of a whole set of ready solutions 
for known problems, which has been acquired during life-time through 
education. Fluid intelligence is the intelligence used for creative solutions in 
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unknown problems. It is important in nonverbal skills and perception of spatial 
relationships. Crystallized intelligence is rather stable, in contrast to fluid 
intelligence which is more unstable and firstly impaired in diffuse brain 
damage. These concepts are in accordance with the study of Kardel, who found 
that after a portocaval anastomosis patients performing intellectual tasks were 
less impaired in daily life than patients who worked with their hands! The 
white collar worker will mainly use his crystallized intelligence and will, 
therefore, be not much impaired in his daily work. The blue collar worker, on 
the other hand, depends predominantly on his fluid intelligence for his daily 
work, and as a consequence will be more easily impaired. The clinical 
significance of SHE may, therefore, lie in restoring functional impairment in 
these patients. 
The third problem, the physian has to deal with, is whether to treat a 
patient with SHE. Most physicians will be reluctant to treat an isolated 
abnormal diagnostic test in an asymptomatic patient. Automatic treatment of an 
abnormal neurophysiological or neuropsychological test is, therefore, not 
justified, especially since no effect of lactulose therapy could be observed in a 
double-blind trial in patients with cirrhosis and elevated blood ammonia levels. 10 
Therapy appears desirable only for patients with functional impairment. II. 12 No 
data are available which support prophylactic treatment of patients with SHE, 
although SHE is considered to precede the development of clinically overt HE. 
The recent introduction of the TIPS procedure in clinical hepatology provides 
an opportunity to study the course of SHE, and the effect of intervention. 
In summary, the recognition of functional impairment is emerging as the 
key element in subclinical hepatic encephalopathy. In patients with diagnosed 
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SHE the physician should clearly ask for evidence of functional impairment. 
Quality of life asessment in such patients has documented diminished daily 
functioning independent of the severity of liver disease,'2 which strongly 
suggests a relationship between SHE and functional impairment. Progress in the 
area of SHE is to be expected if functional impairment related to SHE can be 
detected reliably in the individual patient in a simple way by the attending 
physician. Future research should be directed in the development and validation 
of such a diagnostic tool. 
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SUMMARY 
SAMENV ATIING 

SummalY. samenvafling 
Subclinical hepatic encephalopathy (SHE) is a syndrome in which patients 
with liver cirrhosis without clinical signs of overt hepatic encephalopathy 
demonstrate a number of quantifiable neuropsychological and/or 
neurophysiological defects. Chapter I gives a review of the literature 
concerning the diagnostic methods used for detection of SHE, its clinical 
significance, and the intervention studies performed. The prevalence of SHE has 
been reported to vary between 30% to 80%. This large variation in prevalence 
is caus~d by a lack of a 'gold standard' diagnostic test, differences in the 
definition of SHE, the diagnostic methods used, the definition of normal values, 
and the patient population tested. Early studies suggested that SHE had clinical 
significance as, theoretically, it would develop in overt clinical encephalopathy, 
and have a negative impact on patients' daily life (e.g., in driving a car, or 
working with machinery). However, recent studies have failed to show the 
negative influence of SHE on fitness to drive. In addition, intervention studies 
have not made use of parameters of daily functioning to monitor the effect of 
treatment efficacy in SHE. Studies in which the clinical relevance of this 
subclinical entity is evaluated should be performed before screening for SHE 
or treatment is recommended. 
Although the arterial ammonia concentration correlates best with the 
severity of hepatic encephalopathy, arterial punctures for investigational 
purposes can cause medical ethical problems in some countries. In Chapter 2 
we compared capillary ammonia levels with arterial ammonia levels 
simultaneously determined with the Blood Ammonia Checker II. Agreement was 
poor as capillary ammonia levels were considerably higher than arterial 
ammonia levels. Furthermore, capillary ammonia measurements showed poor 
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reproducibility. Capillary ammonia measurements are, therefore, unreliable for 
monitoring patients with hyperammonaemic diseases. 
In Chapter 3, two psychometric tests (NCT, SDT) and automated EEG analysis 
were used for the diagnosis of SHE in 137 patients with liver cirrhosis. Results 
show that without the use of age-dependent normal values, the prevalence of 
SHE is largely overestimated. There is poor overlap between abnormal 
psychometric tests and neurophysiological tests, suggesting that both methods 
probably measure different components of SHE. The prevalence of SHE is low 
(14%) in patients with Child-Pugh grade A, and increases to 45% in Child-Pugh 
grade B or C. The most remarkable finding of this study is that older patients 
with an elevated arterial ammonia concentration are more prone to develop SHE 
than younger patients with an equal arterial ammonia concentration. 
The influence of chronic liver disease on patients daily functioning was assessed 
using the Sickness Impact Profile (SIP) questionnaire in 100 cirrhotic patients 
(Chapter 4). The distribution of the SIP scores of the patients with liver 
cirrhosis differed from the reference scores of the normal population. Patients 
with SHE had a worse SIP score than those without SHE. Multivariate analysis 
showed that the impaired daily functioning was not related to age or severity of 
liver disease. The reproducibility of the SIP results was high when the test was 
repeated after a 3-month period. 
In Chapter 5 the effect of a low dose of lactulose (30 grams daily) on 
psychometric tests, spectral EEG, and daily functioning in hyperammonaemic 
cirrhotic patients was evaluated. Forty patients participated in a 6-months 
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double-blind placebo controlled study. No significant changes were seen after 
treatment in the arterial ammonia concentration, psychometric tests, spectral 
EEG and total SIP score in both the lactulose and placebo group. A low-dose 
of lactulose is, therefore, not effective in hyperammonaemic patients with 
respect to SHE and quality of life. Whether patients with SHE and impaired 
quality of life will benefit from effective treatment (higher lactulose dose?) 
remains to be determined. 
Helicobacter pylori infection in patients with liver cirrhosis could be a risk 
factor for hepatic encephalopathy, as H pylori produces large amounts of 
ammonia in the stomach. A study was performed in 11 hyperammoneamic 
cirhotic patients infected with H pylori, in which the effect of H pylori 
eradication therapy on the arterial ammonia levels was assessed (Chapter 6). 
H pylori eradication resulted in a significant reduction of baseline blood 
ammonia levels from 79 Jtmolll to 64 Jtmolli. Ten weeks after treatment the 
mean blood ammonia level had risen to 79 Jtmolll, which was not significantly 
different from baseline values. It is concluded that H pylori eradication does not 
result in a long-term reduction in blood ammonia levels in hyperammonaemic 
patients. Reduction of ammonia after treatment can be explained by the non-
specific effect of amoxycillin on ammonia-producing gut flora, rather than the 
eradication of the ammonia-producing H pylori itself. 
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In Chapter 7 a discussion on the mysterious entity SHE is given. It is 
questionned whether expensive and time consuming tests should be performed 
in patients who do not have any complaints. A proposal is made to screen 
patients with SHE for impaired daily functioning. Future research should be 
directed to the development of simple diagnostic tools, which measure SHE and 
impaired daily functioning. 
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Subklinische hepatische encefalopathie (SHE) is een syndroom waarbij 
patienten met levercirrose zonder klinische symptomen van hepatische 
encefalopathie, afwijkingen vertonen bij neuropsychologisch en/of 
neurofysiologisch onderzoek. Hoofdstuk 1 geeft een literatuur-overzicht van de 
diagnostische methoden die worden gebruikt voor de detectie, de klinische 
betekenis en behandeling van SHE. De prevalentie van SHE bij patienten met 
levercirrose varieert in de literatuur van 30 % tot 80 %. Deze grote spreiding 
wordt veroorzaakt door het ontbreken van een 'gouden standaard' diagnostische 
test, verschillen in de definities van SHE, de gebruikte diagnostische methoden, 
de definitie van normaal en de onderzochte patient populatie. De eerste studies 
suggereren dat SHE van klinische betekenis is, omdat SHE in klinische 
encefalopathie zal overgaan en een nadelige invloed op het dagelijks leven van 
de patient zal hebben (bijvoorbeeld bij het besturen van een auto of bedienen 
van een machine). Recentere studies hebben echter geen nadelig effect van SHE 
op het besturen van een auto kunnen aantonen. Tevens is in de tot nu toe 
verrichte interventie-studies dagelijks functioneren nooit als parameter gebruikt 
ter beoordeling van de effectiviteit van behandeling van SHE. Voordat 
behandeling van SHE kan worden aanbevolen, moe ten eerst studies worden 
verricht naar de betekenis van deze subklinische entiteit. 
Hoewel de arteriele ammoniak concentratie het best correleert met de ernst van 
hepatische encefalopathie, kan het verrichten van arterie-puncties voor 
onderzoeksdoeleinden in veel landen op medisch-ethische bezwaren stuiten. In 
Hoofdstuk 2 werden capillaire met arteriele ammoniak spiegels vergeleken met 
behulp van de zogenaamde Blood Ammonia Checker II. ArterieIe en capillaire 
ammoniak spiegels kwamen slecht overeen, waarbij de capillaire ammoniak 
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spiegels steeds hoger uitvielen. Tevens was de reproduceerbaarheid van de 
capillaire ammoniak metingen slecht. Capillaire ammoniak metingen zijn 
derhalve niet betrouwbaar voor het vervolgen van patienten met 
hyperammonaemische ziekten. 
In Hoofdstuk 3 werden twee psychometrische testen (NCT, SDT) en het 
spectraal EEG gebruikt om SHE te diagnosticeren in 137 patienten met 
levercirrose. De resultaten toonden dat de prevalentie van SHE overschat wordt, 
wanneer geen gebruik wordt gemaakt van normaalwaarden gecorrigeerd voor 
leeftijd. Er was weinig overlap tussen abnormale psychometrische testen en 
abnormale spectraal EEG's, hetgeen suggereert dat beide methoden mogelijk 
een verschillend aspect van SHE meten. De prevalentie van SHE (14%) was 
laag in patienten met Child-Pugh graad A leverziekte en steeg naar 45% in 
Child-Pugh graad B of C leverziekte. Een opmerkelijke bevinding van deze 
studie was dat oudere mensen met een verhoogde arteriele ammoniak spiegel 
een grotere kans hebben op SHE dan jongere patienten met dezelfde arteriele 
ammoniak spiegel. 
De invloed van chronische leverziekte op het dagelijks functioneren van 
patienten werd beoordeeld met behulp van de Sickness Impact Profile (SIP) 
vragenlijst bij 100 patienten met levercirrose (Hoofdstuk 4). De resultaten lieten 
zien dat de verdeling van de SIP scores anders is bij patienten met levercirrose 
dan in de norma Ie populatie. Patienten met SHE hadden een slechtere SIP score 
dan patienten zonder SHE. Multivariaat analyse toonde aan dat het verminderde 
dagelijkse functioneren niet het gevolg is van de leeftijd of van de ernst van de 
leverziekte. De reproduceerbaarheid van de SIP was goed bij het herhalen van 
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de vragenlijst na 3 maanden. 
In Hoofdstuk 5 werd het effect van een lage dosis lactulose (30 gram d.d.) op 
psychometrische testen, spectraal EEG en dagelijks functioneren in 
hyperammonaemische cirrose patienten geevalueerd. Veertig patienten namen 
deel aan een 6 maanden durende dubbelblinde, placebo-gecontroleerde studie. 
Na behandeling werden noch in de lactulose-, noch in de placebo-groep, 
significante veranderingen gezien in de arteriele ammoniak concentratie, 
psychometrische testen, het spectraal EEG en de SIP score. Een lage dosis 
lactulose is derhalve niet effectief in de behandeling van SHE en verbetering 
van kwaliteit van leven bij hyperammonemische patienten. Of patienten met 
SHE en een verminderd dagelijks functioneren baat zuBen hebben bij een meer 
effectieve behandeling (hogere lactulose dosering?) dient nog onderzocht te 
worden. 
Helicobacter pylori infectie in patienten met levercirrose zou een risicofactor 
kunnen zijn voor het ontstaan van hepatische encefalopathie, omdat H pylori 
grote hoeveelheden ammoniak in de maag produceert. Een studie werd verricht 
in 11 hyperammonaemische cirrose-patienten, die met H pylori gelnfecteerd 
waren, waarbij het effect van H pylori eradicatie-therapie op de arteriele 
ammoniak-spiegels werd bestudeerd (Hoofdstuk 6). H pylori eradicatie leidde . 
tot een significante daling van de arteriele ammoniak spiegels van 79 /tmol/I 
naar 64 /tmol/l. Tien weken na behandeling was de gemiddelde arteriele 
ammoniak spiegel echter weer gestegen naar 79 /tmol/I, wat niet significant 
verschillend was van de uitgangswaarde. Er wordt geconcludeerd dat H pylori 
eradicatie niet leidt tot een blijvende verJaging van de ammoniak-spiegels in het 
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bloed van hyperammonaemische patienten. De verJaging van de ammoniak-
spiegel na behandeling kan verklaard worden door het aspecifieke effect van 
amoxicilline op de ammoniak-producerende darmflora in plaats van door de 
eradicatie van H pylori. 
Hoofdstuk 7 is een discussie over de mysterieuze entiteit SHE. Men dient zich 
af te vragen of het zinvol is om kostbare en lijdrovende diagnosliek Ie 
verrichlen bij patienten die geen klachten hebben. Een voorslel wordt gedaan 
om in loekomstig onderzoek naar SHE meer aandacht Ie besteden aan de 
diagnostiek van verminderd dagelijks functioneren. 
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